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Summary: There is strong evidence suggesting that diabetes mellitus (DM) triples the risk of 
tuberculosis (TB) disease and worsens TB outcomes. South Africa carries a heavy burden of 
TB which is primarily driven by the human deficiency virus (HIV). The burden of non-
communicable disease is also growing rapidly in South Africa. There is however lack of up to 
date data on the burden of DM and the associated risk factors among TB patients. This 
dissertation is based on a cross-sectional study which sought to assess the prevalence of DM 
and impaired glucose tolerance (IGT) and determine the risk factors associated with DM among 
TB patients.  
 
Methods: This cross sectional study forms part of a case control study that aimed to assess the 
association between DM and TB and the population attributable risk of TB due to DM in 
Khayelitsha, a high HIV and TB setting. The TB patients recruited in the case control study 
formed the population of this current cross-sectional study. Based on oral glucose tolerance 
test, fasting blood glucose, glycated haemoglobin and self-report the prevalence of DM was 
determined. Bivariate and multivariate logistic regression analyses were performed to assess 
risk factors associated DM among TB patients. Due to significant differences between male 
and females with respect to various characteristics, we also stratified the data by sex during 
analysis. 
 
Results: The prevalence of DM among the TB patients was 39/288 (13·54%; 95% confidence 
interval (CI) 10·03-18·03%); DM was previously diagnosed in 11/39 of the DM patients and 
6/11 of these were receiving DM medications. The prevalence of IGT was 139/288 (48·26%; 
95% CI 42·51-54·07%). Common co-existing conditions among the patients were 
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hypertension (18·06%; 95% CI 14·01-22·96%) and HIV (64·31%; 58·52-69·71%). On 
multivariate analysis, positive family history of DM (odds ratio (OR): 3·20, 95% CI 1·61-8·83, 
p=0·025), hypertension (OR 4·49; 95% CI 1·536-13·147; p=0·006) and waist circumference 
(OR: 1·03; 95% CI 1·00-1·06; p=0·027) were significantly associated with DM. In the 
multivariate model for females, only gestational DM was (OR 14·55; 95% CI 2·03-103·59; 
p=0·008) was associated with DM and in the model for males, hypertension (OR 3·30; 95% 
CI 1·17-9·33; p=0·024) and the age category > 45 years (OR 11·05; 95% CI 2·09-58·35; 
p=0·005) were associated with DM. There were no interactions between sex and BMI.   
 
Conclusions: The high prevalence of IGT highlights the likely trajectory of DM prevalence 
without intervention. With strong evidence that DM increases the likelihood of TB disease and 
has adverse effects on TB outcomes, the growing burden of DM in a high HIV and TB burden 
settings such as ours pose threats to TB control. Interventions need to prioritise DM screening 
and management for high risk groups: risk groups (patients with: hypertension, family history 
of DM, high waist circumference; men with age > 45 years and hypertension; females with 
gestational DM) may be efficient. Interventions to prevent the development of DM among 
patients with ITG will also be essential. It is recommend that our health systems consider an 
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0.6 LIST OF DEFINITIONS 
 




 People who are started on TB treatment without bacteriological confirmation 
of disease. This includes patients started on treatment based on: 
 chest x-ray abnormalities that are consistent with active TB 
 the history and clinical picture suggestive of PTB or EPTB 
 histological and biochemical tests suggestive of TB (2). 
 
Diabetes mellitus DM A chronic disease which arises when the pancreas does not produce enough 
insulin or when the body cannot use the produced insulin effectively.  The 
main types of DM are type 1 and 2. People with type 1diabetes do not produce 





IGT People whose blood glucose levels are high but not as high as those in people 
with diabetes are said to have impaired glucose tolerance (commonly referred 




ETB TB disease involving organs other than the lungs: e.g. pleura, lymph nodes, 




FPG/FBG Measure of glucose level after no eating for at least 8 hours (1). 
Glycosylated 
haemoglobin 
HBA1c HbA1c reflects average plasma glucose over the previous eight to 12 weeks. 
This test can be performed at any time of the day and does not require any 
special preparation such as fasting (4). 
 
Latent TB infection LTB When one has TB infection but does not show symptoms of TB and is not 
infectious but is at risk of developing active disease and becoming infectious 
(3). 
 
Oral glucose tolerance 
test 





PTB TB disease involving the lung parenchyma. 
Relapse  Reactivation of latent TB. 
Smear negative PTB  Smear microscopy negative for AFBs (2). 
Smear positive PTB  A  positive acid-fast bacilli (10-99 AFB per 100 oil immersion fields) in at 




 The collection date of the first sputum sample that is reported as negative, after 
a previous positive culture for TB (2). 
 
Tuberculosis  TB An infectious disease caused by the bacterium Mycobacterium tuberculosis 
(Mtb) that is mainly transmitted through inhalation and is characterized by 
cough, fever, shortness of breath, weight loss, and the appearance of 
inflammatory substances and tubercles in the lungs (3). 
 
Xpert MTB/RIF  An automated molecular platform to detect Mtb and rifampicin resistance 
testing by targeting specific mutations. It is approved for use directly on raw 
sputum and results should be available within 2 hours in the laboratory but 
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Tuberculosis (TB) remains the deadliest infectious bacterial disease worldwide, causing 
approximately 9 million new infections and 1.5 million deaths each year (3). Although the 
global TB incidence trend is declining (3), TB remains a major health problem in most low- 
and middle- income countries (LICs and MICs). South Africa (SA) is one of these countries 
and is ranked among the highest TB burdened countries and was listed among the top six 
countries with high TB incidence reporting between 410 000 and 520 000 new cases in 2013 
(3). Factors that continue to fuel the TB epidemic include low socio-economic conditions such 
as malnutrition, overcrowding and poor housing (5). Other factors include alcoholism, silicosis, 
tobacco use, and immunosuppressive conditions such as the human immunodeficiency virus 
(HIV) and diabetes mellitus (DM) (3,6).   
 
Strong evidence suggests that  DM, increases the risk of TB disease (7,8). A systematic review 
of cohort studies showed that DM triples (relative risk (RR) 3.11, 95% confidence interval 
(CI): 2.27 – 4.26) the risk of TB disease  (9). In India, it was estimated that DM accounts for 
approximately 15% of pulmonary TB cases (11). It has also been shown that screening for DM 
among TB patients yields a prevalence of DM ranging between 1.9% and 39% (10). The 
biological plausibility of this TB-DM association is based on hypotheses that DM patients have 
impaired immune response, dysfunction of alveolar macrophages, micronutrient deficiency 
and pulmonary microangiopathy (12,13). Adverse effects on TB outcomes such as the 
increased risk of treatment failure, relapse, resistance and death are also attributed to DM 
(14,15). There are other suggestions that TB may induce DM by impairing glycaemic control 




The World Health Organisation (WHO) recommends bi-directional screening of TB and DM 
(12), however most countries still lack integrated health systems for co-managing both non –
communicable diseases (NCDs) and infectious diseases (IDs) (17). This link between TB and 
DM could therefore provide an opportunity for co-management of these diseases and to 
improve care by early case detection, better clinical management and easier access to treatment 
of both conditions (17,18). 
 
It must be noted that the association between TB and DM emerged almost a thousand years 
ago (19). However the discovery of insulin and antibiotics to manage DM and TB respectively, 
reduced the urgency towards further investigations to better understand this link (20). The link 
between these two diseases has become more apparent and significant in recent years as the 
global burden of DM is rapidly increasing in developing countries where TB remains 
prominent. While it is known that 95% of TB cases are from LICs and MICs (3), almost 80% 
of DM cases are also from these countries (1).  
 
The global burden of DM is rapidly increasing and is expected to increase further in LICs and 
MICs where rapid development and urbanisation are currently taking place. The burden of DM 
globally and in Africa was estimated at 382 million and 19.8 million in 2013 and is projected 
to increase to 592 million and 41.4 million in 2030, respectively (1). In Sub-Saharan Africa, 
SA is reputed to have among the highest prevalence of DM, with approximately 2.6 million 
people living with DM (1). This rapid growth of DM disease, especially type 2 DM is attributed 
to nutritional and lifestyle transitions which involve increased consumption of refined fats and 
sugars combined with physical inactivity, increasing levels of obesity, alcohol consumption 




Diabetes mellitus and TB provide a good example of an interaction between an ID and an NCD 
which may be mediated by common risk factors such as poor nutrition, smoking and alcohol 
(18). These interactions contribute to the ongoing epidemiological transition taking place in 
most LICs and MICs, which is characterised by increasing multi-morbidity of chronic IDs and 
NCDs. Given the evidence that DM increases the risk of TB, the increasing burden of DM in 
countries already burdened by TB is a potential threat to current TB control measures and may 
imply a heavier strain on the country’s health systems.   
 
The Millennium Development Goals (MDG) included targets to reduce the global TB 
incidence, and to halve the prevalence and death due to TB by the year 2015 in comparison 
with 1990 levels (3). Although the TB incidence in declining, it is at a very slow rate (3), and 
the latter targets of halving deaths and prevalence by 2015 compared to 1990 were not met 
(25). These goals were not achieved partly due to the prevailing need to address other risk 
factors of TB. A mathematical modelling study reported results suggesting that if interventions 
reduce the incidence of DM by 35% by 2025, 7.8 million (6.7-9.0 million) TB cases and 1.5 
million (1.3-1.7 million) TB deaths could be avoided by 2035 (26). 
 
A.2 Rationale of the study 
South Africa (SA) is ranked among the top 22 TB High Burden Countries, has among the 
highest incidences in the world and a high TB mortality with 25 000 people dying each year 
(3). Although the TB incidence has declined in SA, the MDG to halve the prevalence and 
deaths due to TB by 2015 in comparison to 1990 levels, have not been attained (27). The 
country is also currently undergoing demographic and epidemiological transitions 
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characterised by an aging population and co-morbidity of epidemic IDs such as TB and HIV 
with NCDs which include DM (23). SA is also recognised as the most urbanised country in 
Sub-Saharan Africa with 62% of the population living in urban (28). These transitions are 
mainly driven by development processes such as urbanisation, lifestyle changes and increased 
physical inactivity (18). In 2013, approximately 2.6 million South Africans were living with 
DM (8,20). In 2009 a  cross-sectional study conducted in urban townships near the Cape Town 
including Khayelistha, reported the prevalence of DM to be 13.1% (95% CI 11.0-15.1%) (22).   
 
Well known to be the strongest risk factor for TB, HIV remains highly prevalent in SA affecting 
approximately 12% of the population in 2012 (30). The increased use of antiretroviral therapy 
(ART) in the country has led to increased long-term survival. However, it is suggested to be 
associated with aging effects and co-morbidity with metabolic diseases which include DM (31). 
It is thought that in settings with high HIV infection, the effect of DM on TB could be masked 
by the effect of HIV on DM as well as the strong association between HIV and TB (32). It is 
therefore essential to investigate the magnitude of the interaction between DM and TB in 
people living with HIV. 
 
Identifying modifiable risk factors which predispose both TB and DM could be useful in 
determining which population groups to target and prioritise for intervention. Quantifying the 
prevalence of DM among TB patients is also essential to assess the expected strain on health 
facilities. Very few studies from LICs and MICs have sought to explore the association between 
TB and DM. In addition, the majority of studies most were conducted among Indian, Asian 
and Caucasian populations but very few studies among African populations. To our knowledge, 
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there is no published study in the context of SA, which has examined the association between 
TB and DM nor quantified the disease burden of DM among adult TB patients.  
 
A.3 Aim and Objectives of the Study 
A.3.1 Aim of the study 
This study aims to quantify the prevalence and determine determinants of DM among TB cases 
in Khayelitsha, a low socio-economic setting, which is a predominantly black African 
population and where TB and HIV are endemic. 
 
A.3.2 Objectives of the study 
1. To quantify the prevalence of DM and impaired glucose tolerance (IGT) in TB patients.  
2. To determine risk factors associated with DM in TB patients. 
 
A.3.3 Anticipated impact of this study:  
Public health impact: This study hopes to contribute towards the field of public health by 
informing the care of DM that could be effectively incorporated within existing TB programs 
and how finances could be potentially allocated to assist in this regard. In addition, we hope to 
identify high risk groups which need to be prioritised for implementing screening and 
management intervention programmes. 
Body of knowledge: This study also seeks to provide quality data on the link between TB and 





A.4.1 Study population and setting 
This study will be conducted at Ubuntu Clinic, an integrated TB/HIV and the largest TB clinic 
in Khayelitsha.  Khayelitsha is a township situated in the outskirts of Cape Town with a 
population of over 500 000 and predominantly constitutes black Africans. In 2011 the HIV 
antenatal prevalence in Khayelitsha was estimated at 37% (33) and the TB case notification 
was 1500 per 100 000 population (34). The main contributor of TB in this township is HIV 
with the prevalence of HIV-TB co-infection at 70% (34) .   
 
A.4.2 Study design and sampling 
This will be a cross-sectional study which will include interviews to document risk factors for 
DM. The cross-sectional study forms part of a case control study that recruits TB cases and 
controls (TB suspects confirmed to not have TB) presenting at the Ubuntu Clinic. For the 
current study, the same TB cases recruited in the case control study will be recruited before TB 
treatment is initiated and used as the sample for this study. 
 
The main aim of the case control study is to investigate the population attributable risk of TB 
due to DM in a high HIV burden setting and to determine the best screening algorithms for DM 
and TB among 1) newly diagnosed TB patients and 2) patients attending diabetic clinics, 
respectively. Protocol and Ethical approval of the main study are attached in Part D, the 
appendices to the dissertation (D.1 Study protocol for the main study and D.2: Ethics 




A.4.3 Sample size 
We will manually compute the required sample size using the formula (n = Z2p (1-p)/d. Where 
Z = 1.96 represents the normal distribution standard deviation based on the 5% significance 
level (for 95% confidence level); p = 16.5% the prevalence of DM among TB patients in a 
Ugandan study (33); d = 0.05% represents the desired margin of error for our estimation.   
 
A.4.4 Participant inclusion criteria 
To be eligible to participate in the study, patients have to be 18 years or older, consent to 
participate, have confirmed TB status and should not have initiated TB chemotherapy.   
 
A.5 Measurements and instruments 
A.5.1 Defining TB cases 
Trained clinical research workers will administer the TB suspect screening tool – a structured 
questionnaire (Part D, D.3: TB suspect screening tool) to the consenting TB patients. This 
questionnaire will record demographic, medical and drug history, HIV status and (if positive) 
date of initiation of ART, regimen, and CD4 count, as well as clinical, microscopic and 
radiological characteristics of TB at diagnosis. Additionally, other risk factors for diabetes such 
as family history, anthropometric measurements including body weight and height for 
calculating the body mass index (BMI), and waist circumference will be recorded. 
 
All study participants will have their TB status confirmed by a medical doctor, following a 
clinical process as per the South African National Tuberculosis Management Guidelines (2) 




Table A-1: The definition of a tuberculosis case as recommended by the World Health 
Organisation (3) 
Type of TB case Description 
Bacteriologically confirmed A patient from whom a biological specimen is positive by smear 
microscopy, culture or WHO-approved rapid diagnostic test (such as 
Xpert MTB/RIF). 
 
Clinically diagnosed  A patient who does not fulfil the criteria for bacteriologically 
confirmed TB but has been diagnosed with active TB by a clinician 
or other medical practitioner who has decided to give the patient a full 
course of TB treatment. Diagnosis based on:  
 chest x-ray abnormalities consistent with active TB 
 the history and clinical picture suggestive of PTB or EPTB 
 histological and biochemical tests suggestive of TB 
 
Pulmonary  Any bacteriologically confirmed or clinically diagnosed case of TB 
involving the lung parenchyma or the tracheobronchial tree. 
 
Extra-pulmonary  Any bacteriologically confirmed or clinically diagnosed case of TB 
involving organs other than the lungs, e.g. pleura, lymph nodes, 
abdomen, genitourinary tract, skin, joints and bones, meninges 
 
TB: tuberculosis; MTB/RIF: Mycobacterium tuberculosis/rifampicin; EPTB: extra pulmonary tuberculosis; 
WHO: World Health Organisation 
 
Two sputum samples will be collected from each TB suspect, and at least two tests of either 
sputum microscopy, Gene Xpert or sputum culture will be performed. We will define an 
individual as a TB case if either one of these conditions hold: 
1. They test positive for the smear microscopy 
2. They test positive for the Gene Xpert 
3. They test positive for the culture positive  
4. Clinically diagnosed positive by a medical doctor  
 
Microscopy results will be first collapsed into three categories: positive if scanty, +, ++, +++; 
negative if 0, and not done if the test was not performed. The characteristics of smear 
microscopy test include high specificity but low sensitivity especially among immune 
suppressed patients such as children and people living with HIV/Acquired immunodeficiency 
syndrome (AIDS) (2,36). The culture test is a gold standard test and has a relatively high 
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sensitivity. A TB suspect will be defined negative if they test negative for all three tests for 
both sputum samples. 
 
Table A-2: Tests to define a confirmed TB case 
Test Positive test (on either one of two sputum samples) Negative test (on both sputum samples) 
Microscopy Scanty: 1-9 AFB per 100 oil immersion field 
+: 10-99 AFB per 100 oil immersion field 
++: 1-10 AFB per 1 oil immersion field (min 50 fields) 
+++: >10 AFB per 1 oil immersion field (min 20 
fields) 
 
0: No AFB per 100 oil immersion field 
 OR AND 
 
Culture  Positive  
 
Negative 
 OR AND 
 
Xpert/RIF  M.tb. detected  
 
M.tb. not detected  
 OR AND 
 
Clinical 
diagnosis by a 
medical 
doctor 
• chest x-ray abnormalities consistent with active TB 
• the history and clinical picture suggestive of PTB or 
EPTB 
• histological and biochemical tests suggestive of TB 
Showing no symptoms suggestive of TB  
AFB: acid fast bacilli; TB: tuberculosis; Mycobacterium tuberculosis: M.tb; PTB: pulmonary tuberculosis; 
ETB: extra pulmonary tuberculosis 
 
 
A.5.2 DM screening in TB patients 
Before TB chemotherapy initiation, blood samples will be collected from the TB patients to 
measure their fasting blood glucose, oral glucose tolerance test (OGTT), and glycosylated 
haemoglobin (HbA1c). All blood samples will be sent to the National Health Laboratory 
Services (NHLS) for analysis. A patient will be considered to have DM if:  
1. the diagnosis is known at presentation, 
2. they are taking oral hypoglycaemic therapy and/or insulin 




Table A-3: Criteria for diabetes diagnosis (37,4,38) 
Test Description 
Glycosylated haemoglobin  
 
HbA1C ≥6.5% 
The test should be performed in a laboratory using a 
method that is National Glycohaemoglobin 
Standardisation Programmes certified and standardized 
to the Diabetes Control and Complications Trial assay.* 
 
OR 
Fasting Blood Glucose 
 
FBG ≥126 mg/dL (7.0 mmol/L) 
Where fasting is defined is considered as no caloric 




Oral Glucose Tolerance Test 
 
2-h plasma glucose ≥ 200mg/dL 
(11.1mmol/L) 
During an OGTT. The test should be performed as 
described by the WHO, using a glucose load containing 
the equivalent of 75 g anhydrous glucose dissolved in 
water.* 
*In the absence of unequivocal hyperglycaemia, result should be confirmed by repeat testing  
 
Newly diagnosed DM patients will be referred to the DM clinic at Khayelitsha Day hospital, 
which is located at the same premises as Ubuntu clinic.  
 
A.5.3 WHO-STEPS questionnaire   
Additional to variables collected using the TB suspect screening tool, consenting participants 
will be interviewed using a structured questionnaire (Part D, D.4: WHO STEPS instrument) 
which was adapted from the WHO-STEPS questionnaire (39) . The variables to be documented 
also include anthropometric measurements (weight, height and waist circumference), 
demographic information (sex, race, age, education level and income), behavioural 
measurements (alcohol, tobacco use and physical activity) and biochemical measurements 




A.5.4 Validity of measurements 
All diagnostic tools that will be used in this study are standard and were validated by the WHO. 
The TB screening tool (questionnaire) is adherent to WHO guidelines and is recommended by 
the South African National Tuberculosis Management criteria (2). For screening DM, the 
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HBA1c, FBG and OGTT tests recommended and validated by WHO will be used (37,4,38). 
WHO STEPS instruments which will be used for recording chronic disease risk factors is also 
WHO validated (39). 
 
A.6 Data Management 
The completed TB suspect screening questionnaires will be captured into eKapa database by 
trained data capturers. eKapa is an electronic healthcare database adopted by the Western Cape 
Department of Health for monitoring and evaluation of HIV/AIDS and TB healthcare 
programmes in the province. The responses collected using the adapted WHO STEPS 
questionnaire will be captured into Microsoft Access. The data from these databases will be 
merged using unique identifiers for each study participant. Only the principal study 
investigator, data capturers, data manager and other study related personnel (with special 
permission) will access these databases using passwords. Completed questionnaires will be 
kept safe and secure in cupboards.  
 
A.7 Data Analysis 
All statistical analysis will be performed using Stata version 12 (StataCorp LP, 4905 Lakeway 
Drive, College Station, Texas 77845, USA).  
 
Statistical significance will be determined using p <0.05 and 95% confidence intervals where 
necessary. Depending on the type of data collected, numerical or categorical data and 
appropriate statistical methods to assess their distributions and nature will be used. Continuous 
variables will be assessed for normality using graphical methods such as histograms, graph box 
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plots and statistical tests such as the Shapiro-Wilk test. Normally distributed data will be 
described using means and standard deviations. Non-normality data will be described using 
medians and interquartile ranges. Categorical data will be described using proportions and their 
intervals. The prevalence of DM will be based on gold standard diagnostic tests, HbA1c, FBG 
and OGTT.  
 
The main outcomes of the analysis will be the number and proportion of TB patients with DM 
diagnosis and IGT with 95% confidence intervals (CIs). To identify and adjust for confounding 
variables TB patients with DM diagnosis will be stratified by some of the risk factor variables 
(i.e. sex), odds ratios with 95% CIs around them will be calculated to elucidate differences 
between strata. To assess risk factors associated with DM among the TB patients, multivariate 
logistic regression analysis will be used to build a statistical model and estimate the odds ratios 
with 95% CI around them. The best fitting model will be built using a manual stepwise 
procedure of comparing different nested models using the likelihood ratio test. The Akaike's 
Information Criterion (AIC) will also be used to assess better models.  
 
A.8 Ethical considerations 
A.8.1 Informed consent, confidentiality and benefits 
This study is a subset of a larger research project approved by the University of Cape Town 
Human Ethics committee (Ref No: 403/2011).  
Informed consent: Consent will be voluntary and obtained from all the participants. An 
information sheet available in both English and isiXhosa will be given and read to participants 
to explain what the study is about.  
14 
 
Confidentiality: Confidentiality and safety will be ensured by securing all the documents 
using unidentifiable keys, password protection in the databases and restricting access to data 
appointed personnel and principal investigators. 
Benefits: The benefits of the study for all participants (TB patients) will include TB 
chemotherapy and those who test HIV positive will be offered counselling and offered to 
initiate antiretroviral therapy (ART) if eligible. Participants with confirmed DM status will be 
referred to a DM clinic for standard care treatment. Potential risks and harm in this study will 
be very minimal, however, minor discomforts through a prick of a needle may be experienced 
by the participants during blood sample collection. The overall impact of this study (outlined 
in A.3.3) will benefit the study participants and the community at large. 
 
A.8.2 Justification for the inclusion of ethnicity and its value to study results 
Evidence highlights the existence of ethnic disparities in health outcomes and access to health 
services which are generally a result of ethnic discrimination (40–42). Though most of these 
disparities are associated with genetic vulnerability and socioeconomic factors (1), 
socioeconomic status underpins majority of these disparities (1). South Africa is an ideal 
example illustrating how past ethnic discrimination has led to differential exposure to 
environmental risks to certain diseases and has shaped the socioeconomic structure according 
to ethnic groups (42).  
 
Ethnicity and genetics are acknowledged to increase the risk of DM, while low socioeconomic 
status is associated with both DM and TB (3,5,1). We include ethnicity, not primarily as a 
determinant of either TB or DM, but as a marker of risk factors which predispose either or both 
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of these two diseases. Including this variable allows us to explore the associations between 
ethnicity and risk factors for either TB or DM.  
 
Studies which have assessed the association between TB and DM have suggested that the 
strength of the association varied across different ethnic groups, age groups and different 
geographies (9). Very few studies were conducted among African populations to assess the 
association between TB and DM. In particular, none from South Africa have yet assessed the 
association between these two diseases nor quantified the burden of DM among TB cases. By 
having our study conducted among the African population, it contributes towards filling the 
gap in the literature on the burden of DM among TB cases and magnitude of the association 
between the two. It is also an opportunity to compare our study results with study results from 
other ethnic groups and geographical settings.  
 
A.9 Reporting 
This study will be conducted for the partial fulfilment of Master of Public Health (MPH) 
Epidemiology degree. The final report with findings will be submitted to the University of 
Cape Town for assessment. The findings will be published in an academic peer-reviewed 

















Dec ’15 – Feb ’16 
Part A: study protocol and 
literature review  
      
 
Submit study protocol for ethics 
approval 
      
Part B: structured literature 
review 
     
 
 
Data cleaning and analysis *; 
Part C: journal manuscript 
      
 
Submit final dissertation       
 
*Data collection in the main (case-control) study took place between Jan 2014 and Aug 2015. 
 
A.10.2 Budget and costs 
No costs are anticipated to be incurred during this study as it is a subset of a larger study in 
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Several studies have suggested that diabetes mellitus (DM) increases the risk of tuberculosis 
(TB). The rapidly increasing burden of DM presents new challenges to TB control especially 
in low- (LIC) and middle- (MIC) income countries where TB is also endemic. Very little is 
known, about the magnitude of the burden of DM among TB patients and extent of the strength 
of association between TB and DM and in these LICs and MICs.  
 
B.2 Aims and objectives 
This structured literature review was guided by the research question: What is the prevalence 
of diabetes mellitus among tuberculosis patients and what are the risk factors for diabetes 
among TB patients? We aimed to review and appraise existing epidemiological studies which 
reported the prevalence of DM among adult TB patients and which also assessed risk factors 
associated with DM among TB patients. We also reviewed studies which assessed the impact 
of DM on TB outcomes, in addition to reporting the prevalence of DM among TB patients. The 
reviewed literature was summarised based on the following themes: 
 The risk factors associated with DM among TB patients 
 Screening for DM among TB patients and associated methodological issues  
 The prevalence of DM among TB patients 
 The magnitude of association between DM and TB  
 The impact of DM on TB treatment outcomes  
 Comorbidity with HIV  





B.3.1 Search Strategy 
We searched PubMed, Scopus and reference lists of papers on the related subject to select 
relevant articles. The search strategy included the following key terms: “prevalence”, 
“epidemiology”, “risk factors”, “determinants”, “diabetes mellitus”, “tuberculosis” “outcome” 
and “treatment”.  
 
B.3.2 Study selection and extraction 
The search strategy aimed to identify and include epidemiological studies which reported the 
prevalence of DM and associated risk factors among adult TB patients, the association between 
DM and TB and on the impact of DM on TB treatment outcomes. Studies were restricted to 
the English language, and we included studies published until August 2015 when the literature 
review was conducted. We excluded studies which were non-English, had non-human subjects 
and those conducted among children and among the elderly only (age > 65). We also excluded 
those which did not report or allow the computation of the prevalence of DM among TB 
patients. The included studies also depended on their availability and accessibility from the 
internet and the University of Cape Town’s Library. We scanned through titles and abstracts 
to identify those which included the key search terms and then selected those which met our 






B.4 Results  
The refined search strategy yielded 128 articles and, of these, 45 articles met our inclusion 
criteria. Fifteen were cross sectional and retrospective descriptive studies, primarily 
quantifying the prevalence of DM among TB patients and risk factors associated with DM 
among TB patients. Eleven assessed the association between TB and DM, only two were cohort 
studies, one retrospective and one prospective and the others were case control studies. 
Eighteen studies assessed the impact of DM on TB treatment outcomes, most of these were 
cohort studies. The studies were summarised in three tables, categorised by the World Bank 
regions and income categories. This categorisation is useful as it allows comparison of studies 
with similar attributes and is suggestive of the demographic characteristics such as 
socioeconomic setting and the ethnicity of the populations from which the studies were 
conducted. Table B-1 summarises the reviewed descriptive studies which primarily reported 
the prevalence of DM among TB patients and the risk factors associated with DM among TB 
patients; Table B-2 summaries the analytical studies which reported the prevalence among TB 
patients and comparison populations, and the association between TB and DM. Table B-3 
summarises the studies which assessed the influence of DM on TB treatment outcomes: 
relapse, recurrence, resistance, sputum conversion, treatment failure and death. 
 
B.4.1 Risk factors associated with DM among TB patients  
Globally, the risk factors of DM in the general population are well documented and include 
obesity, poor diet, physical inactivity, increasing age, ethnicity and high blood glucose levels 
during pregnancy (1).  However, it is unclear whether these risk factors are shared among TB 
patients. In the reviewed studies, the factors that were consistently identified as risk factors of 
DM included increasing age (2–14), family history, high body mass index (BMI) and obesity 
6 
 
(3,4,6,9,13). Some studies found DM and TB co-morbidities to be more common among men 
(2,3,5,8), while others  found it to be common among women (10,14). A suggested reason for 
the high DM prevalence among men is that they usually have accumulated risk from other risk 
factors such as smoking and alcohol consumption. Among women, it could be due to more 
sedentary lifestyles (stay-at home and care taking). 
 
Behavioural factors such as sedentary lifestyle (4,9), increased tobacco smoking and alcohol 
drinking (6,9,11,12) showed to increase the risk of DM in some studies, but there are other 
studies that show no association. For example, in a Ugandan study assessing the prevalence 
and risk factors of DM among TB patients (15), no association was found between DM and 
any of the mentioned above behavioural factors. The authors did not suggest any possible 
explanations for these observations, however it could be because the prevalence of risk factors 
for DM in the study population was generally low. For instance, the mean BMI was 17.4 kg/m2, 
which indicates low risk for obesity and possibly a lower risk for DM. In another study by 
Faurholt-Jepsen et al in Tanzania, severe underweight was associated with DM (3). They 
suggested TB could have caused this weight loss (3). These findings suggest that predictors of 
DM among TB patients depend on the underlying characteristics of the studied population such 
as co-morbidities with other diseases, the prevalence of risk factors of DM in the back ground 
population and possibly the socioeconomic setting. 
 
Socioeconomic factors which have been associated with a higher prevalence of DM  include 
urban residence (8), and low income (9,13). Wang et al showed that higher income was 
positively associated with outdoor activity and negatively associated with DM among 
pulmonary TB patients (13). Other studies also found DM to be higher among those with low 
education attainment (11,12). In studies conducted among heterogeneous populations, ethnicity 
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was associated with DM (12,14,16), with higher DM prevalence among American Indians, 
followed by Pacific Islanders, African Americans, Hispanics and then by Asians and American 
whites (16). The risk of DM attributable to ethnicity is likely to be through its association with 
genetic vulnerability (17,18), ethnic-associated behaviour and life style and socioeconomic 
determinants of health such as disparities in access to health care (19).   
 
Although not explored and discussed by most studies, it is also essential to consider the fact 
that DM has multifactorial risk factors and that some risks are acquired over the life course. 
For example, the risk of DM in some individuals may be mediated by socioeconomic, structural 
or environmental factors which may not be conducive to physical activity or may limit access 
to affordable, healthy food. Through the life course consideration, we need to recognise that 
the development of DM during adult life may be due to early life risk conditions such as 
maternal malnutrition during pregnancy and low birth weight (20,21). Knowledge about the 
risk factors of DM among TB patients is important in identifying groups which could be 
targeted for interventions such as preventative measures for individuals at low risk, and 
screening and treatment for those at high risk. 
 
B.4.2 Screening for DM among TB patients 
The majority of the reviewed studies used at least one of the WHO recommended DM 
diagnostic criteria (22). It has been observed that TB induces a transient phase of 
hyperglycaemia (23) which may overestimate the prevalence of DM among TB patients 
(23,24). Therefore, the time period at which the test for DM are performed in relation to the 




To reduce the potential effect of TB induced hyperglycaemia, various methods and diagnostic 
techniques could be used. For instance, it may be ideal to test TB patients for DM in less acute 
conditions or at a particular point during their TB treatment because it is suggested TB-related 
hyperglycaemia dissipates after effective TB treatment (25). Another way to improve the 
reliability of DM tests among TB patients may be to perform DM confirmatory tests. However, 
more research is required to verify the optimal time points and number of tests required. It is 
important that epidemiological studies assessing the prevalence of DM among TB patients 
employ methods or techniques which will account for and minimise the potential effect of TB 
induced hyperglycaemia on DM diagnosis.  
 
Several studies (9,11–13) mentioned performing at least two tests to confirm DM diagnosis 
although the time points were not specified. The glycated haemoglobin (HbA1c) diagnostic 
tool has the potential to improve the validity of measuring DM. This measurement reflects the 
average blood glucose level over two to three months and is less likely to be influenced by the 
transient acute stress hyperglycaemia (26). Very few studies (8,9,11,27) used the HbA1c tool 
to diagnose DM possibly because it is relatively expensive and was recommended by the WHO 
only fairly recently in 2011 (26). Although some measures were taken to reduce the potential 
overestimation of DM due to the transient hyperglycaemia in some TB patients, the resulting 
DM prevalence was still high, possibly due to the methods and manner in which the studies 
were conducted. 
 
There are several other methodological issues which may have affected the reliability of the 
estimated prevalence of DM among TB patients. Firstly, the majority of the reviewed studies 
were health facility-based and used convenient sampling methods. Secondly, the prevalence 
estimated from such studies is biased and not necessarily representative of the general 
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population. To address this issue, a few studies attempted to use relatively large samples and 
cluster-randomised sampling of health facilities (6,8,13). The use of self-reported DM status is 
another factor which has shown to underestimate the true prevalence of DM (28). Furthermore, 
the use of medical records and disease coding from insurance databases to classify disease 
status is inherently subject to many errors including non-differential misclassification which 
may underestimate the prevalence of DM. Nonetheless, the few studies in which DM was self-
reported still found a relatively high prevalence of DM (6,7,29). Given the clinical condition 
of TB and methodological issues which potentially affect the measurement of DM, it is 
essential to consider how the reported prevalence of DM may be affected.  
 
B.4.3 The prevalence of DM among TB patients 
The reported prevalence of DM among TB patients in the reviewed studies ranged from 2.1% 
in South Africa in 1980 (5) to as high as 44% in Kerala, India in 2012 (8). With respect to 
geographic region, the studies which reported high DM prevalence among TB patients were 
those from South Asia (SAS) (range: 25% - 44%) followed by those from the Latin America 
and Caribbean (LAC) (range: 14% - 39%), East Asia and Pacific (EAP) (range: 6.3% - 39%) 
and Middle East and North Africa (MENA) (range: 23% - 24%). The majority of countries in 
which these studies were conducted are characterised by low income settings and high 
background TB and DM disease burden. In the descriptive studies (summarised in Table B-1), 
the prevalence of DM among TB patients tends to exceed DM prevalence in the general 
population. Among most case control studies (Table B-2), (16,30–35) the prevalence of DM 
among TB patients is at least double the prevalence of DM among comparison populations 
without TB. These findings suggest that the prevalence of DM among TB patients is 




Globally, the prevalence of DM in the general population is expected to double by the year 
2030 (1). A similar pattern of increasing DM prevalence among TB patients can be expected. 
In Table B-1, within each region, studies are ordered by ascending years, and in some regions 
there is a slight indication of an increasing trend. This increasing trend of DM among TB 
patients was also shown in one study (16) which analysed temporal trends of DM among TB 
patients in San Francisco, USA. This American study showed that among TB patients, the 
prevalence of DM increased from 14% in 2006 to 24% in 2012 with a significant time trend 
statistic (p < 0.01) (16). The burden of DM among TB patients is increasing but is variable 
across geographic regions.  
 
The patterns of variability in the prevalence of DM among TB patients may be due to 
demographic differences such as ethnicity and socioeconomic setting and the background 
burden of both TB and DM in the respective general populations. For example, in comparison 
with other regions, studies from Sub-Saharan Africa (SSA) reported relatively low prevalence 
(range: 2.1% – 16.4%). However, due to rapid urbanisation, nutritional and lifestyle transition 
(36,37) occurring in this region, majority of the increasing DM is expected to be contributed 
by this region (1). A few studies (12,14,16) have shown that DM is more prevalent among 
Indians, Filipinos, Asians and Hispanics. From the three tables (Table B-1, Table B-2 and Table 
B-3) it could be seen that the regions with high DM prevalence are those predominantly 
inhabited by people of these ethnicities. The high prevalence of DM among TB patients 
strongly suggests that there is a link between the two conditions.
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TB population and 
sampling method 
DM diagnosis 





Factors associated with 
DM 
Studies from Sub Saharan Africa (SSA) 
(2) Olayinka 2013 NR;                                 
Nigeria 
LIC 5.7% 5% 351 Reviewed sputum smear 
and tuberculin results 
from folders (pulmonary 
+ extra pulmonary); 
Consecutive patients on 
the DOTS (treatment) 
NR FBG ≥ 126  
mg/dl 
Age (41±13.9 years) 
Male 




2011 – 2012;  
Uganda 
LIC 8.5% 4.1% 260 Performed acid-fast 
bacilli, Xpert and 
Sputum smear excluded 
patients on anti-TB drugs 









HIV (OR 0.32, 95% CI 0.13 
– 0 .79). DM not  
significantly associated with 





2006 – 2008; 
Tanzania 
LIC 16.4% 7.8% 1205 Newly diagnosed 




days after TB 
treatment 
FBG ≥ 6.0 
mmol/l or 
OGTT ≥ 11.0 
mmol/l 
Age, high BMI, high waist 
circumference. Sex and low 
BMI interaction – increased 
odds of DM among males 
with low BMI  (<16 kg /m2) 
(OR 2.52, 95% CI 1.34– 
4.74, p = 0.004) 
 (4) Baldé 2006 
 
 
2001 – 2002;      
Guinea 
LIC 3.35%  3.7% * 
(2010) 
388 TB cases on treatment. 
Simple random sampling 
from the countries TB 
registry 




diagnosis by 5 
(range: 1 – 9) 
year  
Capillary blood 
glycaemia test  
Increased age (p < 0.0001),  
obesity (p < 0.005), 
Sedentary lifestyle (p < 
0.0004), DM family history 
(p < 0.04)  
(5) Marais 1980 1977; 
South Africa 
UMIC 2.1% 8.3% 436 NR NR OGTT Males, average age 55 
South Asia (SAS)  
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LMIC 29%   8.6% 223 Randomly selected 4/14 
health facilities. TB 
cases on treatment: new 
and re-treatment cases 
DM preceded 
TB diagnosis in 
20.7% cases, by 
a mean duration 
of 48.7 months 
Self-report of 
DM medication;  
FBG ≥ 126 
mg/dl 
Increasing age, family 
history of DM, alcohol 
consumption 






LMIC 30.6% 8.6% 252 Sputum positive, sputum 
negative and extra 
pulmonary cases on TB 
treatment 
 DM preceded 
TB diagnosis in 
22.2% patients.  
New DM: 7.8%  
Self-report of 
DM medication;  
FBG ≥ 126 
mg/dl 
Increasing age, high BMI, 
systolic blood pressure and 
category of TB treatment, all 
(p<0.05) 
(8) Balakrishnan 2012 
 
2011; 
India – Kerala 
LMIC 44% 8.6% 552 Sampled confirmed TB 
cases form the national 
TB registry using cluster 
randomised  sampling 
Of those with 
DM 
Self-report and 
HbA1c ≥ 6.5% 
Sex (male), age (≥ 50), 
urban residence  
(9) Viswanathan 2012 
 
2011;  
India – Tamil 
Nadu 
LMIC 25.3% 8.6% 827 TB cases registered for 
DOTS 
DM diagnosis 
preceded TB in at 
least 63% 
patients. 
OGTT and  
HbA1c 
Age, family history  
sedentary occupation, higher 
BMI  
Pre-diabetes risk factors:  
waist circumference  
smoking, monthly income  
(39) Gupta 2011                     2005 - 2006; 
India 
LMIC 31.8% 8.6% 192+37 192 microbiologically 
confirmed PTB and 37 
ETB 
NR Medical records Not assessed 
Middle East & North Africa (MENA) 
(10) Golsha 2009 
 
2001 – 2005;  
Iran 
UMIC 23.05% 8.4% 243 Recorded files of 
admitted pulmonary TB 
patients  
 NR FBG ≥ 126 
mg/dl 
Age (≥ 50) and sex (female)  
Latin America & Caribbean (LAC) 








Referred TB suspects. 
Used standard WHO TB 
definitions  
Majority had 8 
years prior  
HbA1c ≥ 6.5%; 
RBG ≥ 200 
mg/dl; 
FBG ≥ 126 
mg/dl 
Increasing age (<0.0001), 
alcohol abuse (0.03), history 




(12) Alladin 2011 2006; 
Guyana 
LMIC 14% 10.2%* 
(2010) 
100 Clinical, radiological, or 
microbiological 
diagnosis and on TB 
treatment 
7% had DM 
diagnosed prior 
TB, 3% 
diagnosed at the 
time TB  




RBG ≥ 200 
mg/dl 
Increasing age, ethnicity, 
low education level, alcohol 




East Asia & Pacific (EAP) 
(13) Wang 2013 
 





(6.3%)                        
9.6% 6382 Newly diagnosed PTB 




56% had known 
DM before TB 
but only 10% 
had their DM 
controlled  
FBG  ≥ 6.1 
mmol/l 
Increasing age, family 
history of DM, higher yearly 
income ($10000 RMB/yuan) 
was negatively associated 
with DM in PTB patients 
Positive sputum smear and 
cavity on chest X-ray  
North America 
(14) Dyck 2007 
 
1991 – 1995; 
Saskatchewan 
HIC 111/2122 11.6% 1375; 
747 
TB registries, national 
insurance data  
DM preceded 




Age sex interaction: females 
aged 50-59 years. Ethnicity, 
Indians: OR 2.7 95% CI: 
1.28 – 5.72 
Saskatchewan: OR 3.9 95% 
CI: 1.58 – 9.67 
DM: diabetes mellitus; FBG: fasting blood glucose; OGTT: oral glucose tolerance test; HbA1c: glycated haemoglobin; TB: tuberculosis; PTB: pulmonary tuberculosis; ETB: extra 
pulmonary TB; BMI: body mass index; NR: Not reported; DOTS: directly observed short course treatment; LIC: low income country, HIC: high income country, LMIC: lower 
middle income country, UMIC: upper middle income county; OR: odds ratio; CI: confidence interval. 
*Used 2010 estimates  (40) 
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B.4.4 The association between DM and TB 
Eleven studies (Table B-2) assessed the association between TB and DM: two were cohort 
studies, (a retrospective (41) and prospective (42)) and the others were case control studies 
(16,30–35,43,44). Only one study from Guinea-Bissau in SSA, found a negative non-
significant association with an odds ratio 0.88 (95% confidence interval (CI) 0.17–4.58 ) (43). 
However, most studies (16,30–34,42,44) reported a positive magnitude of association between 
DM and TB (odds ratios range: 1.28 – 4.7 ) and (relative risks  range: 1.40 – 11.7) The positive 
association seemed to be consistent across geographic regions and study designs. 
 
The strength of the TB-DM association increased after accounting for interactions between DM 
and other risk factors and adjusting for potential confounders such as sex, age, ethnicity and 
co-morbidities such as human immunodeficiency virus (HIV). Suwanpimolkulet et al showed 
a stronger and positive association between DM and TB among Filipinos, followed by Chinese, 
Mexicans and then Americans, with ages greater than 45 years (16).  Methodological issues 
and the clinical condition of TB could have also influenced the measured association between 
DM and TB.  
 
Case control and cohort studies that investigate the link between DM and TB face 
methodological problems which obscure the cause and effect relationship. In case control 
studies, the observed strong association between TB and DM is likely to be reverse causation 
due to stress-induced hyperglycaemia caused by TB (23,24). In an attempt to address this issue, 
Faurholt-Jepsen et al, adjusted for potential confounders and the elevated serum acute phase 
reactants to reduce their effect on blood glucose levels (30). Even after this adjustment, a 
relatively strong association between TB and DM was still observed, particularly among HIV 
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negative patients. In prospective cohort studies (where DM and non-DM patients are followed 
up over time to assess the incident of TB), DM patients are usually on DM treatment. Therefore, 
if the TB risk attributable to DM is mediated by high plasma glucose levels, then DM 
medications may play a role in reducing the risk of TB development and hence reducing the 
true effect of DM on TB development. Besides the potential impact of the clinical condition of 
TB on the measured association, other methodological issues may play a role. 
 
Other methodological issues which could have affected the measure of association between TB 
and DM were duplications of patient data and misclassification of DM status. Several studies 
(16,34,35,42,44) used self-reported DM status, medical records, discharges records, medical 
insurance data and disease coding to classify DM status. These methods are subject to non-
differential misclassification of DM and its likely impact is a nullified measure of the DM-TB 
association. The use of discharge records is subject to duplication (i.e. one patient with multiple 
discharges for something other than DM) of patient data, and the likely impact would be 
overestimation of the reported prevalence of DM or DM-TB association. Despite these 
methodological issues, across a variable studies, the consistent positive association between 
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Age, sex, place of 
residence and BMI 
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DM: diabetes mellitus; FBG: fasting blood glucose; OGTT: oral glucose tolerance test; HbA1c: glycated haemoglobin; TB: tuberculosis; PTB: pulmonary tuberculosis; ETB: 
extra pulmonary TB; LBTI: Latent TB infection; BMI: body mass index; NR: Not reported; DOTS: directly observed short course treatment; NHANES: National Health and 
Nutrition Examination Survey; IHIT: Inuit Health in Transition Study; SIR: sex incidence ratio; OR: odds ratio; CI: confidence interval. 
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B.4.5 The biological plausibility of the DM-TB association and the impact of DM 
on the natural history of TB  
Several hypotheses are proposed to explain the mechanisms through which DM is associated 
with, and impacts TB. Based on existing literature, it is suggested that DM affects every stage 
of the natural history of TB (45–48). Firstly, DM is associated with a reduced cellular immunity 
(45). Patients with concomitant DM and TB are observed to have low T lymphocyte count, 
reduced T-helper 1 cytokine response level and inhibited macrophage function. In addition, 
hyperglycaemia has a direct depressive effect on polymorphonuclear functions such as 
respiratory burst1 and phagocytosis2 (49–51). The combined effect of these suggested 
dysfunctional processes and conditions described above and possibly others not mentioned 
here, contribute to the increased risk of TB among DM patients.  
 
Adverse TB treatment outcomes have been further associated with DM. Efficient killing of 
Mycobacterium tuberculosis (M.tb.) by anti-M.tb.  antibiotics requires support from a fully 
functional immune system (45). Chronic hyperglycaemia is suggested to compromise M.tb  
killing by causing microvasculature complications and reducing lung tissue function for 
optimal immune surveillance (45,52).  Therefore, considering that DM patients have an 
impaired cell-mediated immunity (45), this may partly explain why anti-M.tb treatment is 
inefficient among DM patients with TB and results in poor treatment outcomes. 
 
                                                          
1 The oxygen-dependent intracellular killing of infectious agents in polymorphonuclear cells (49). 




B.4.6 The impact of DM on TB treatment outcome  
Eighteen studies (Table B-3) assessed the impact of DM on TB treatment outcomes. These 
outcomes included: relapse, recurrence, resistance, failure, sputum conversion and death during 
TB treatment (Table B-4). The majority of studies were retrospective in design (31,53–60), a 
few were prospective (27,61–66), one was a nested case control (67) and another was cross-
sectional (68). To classify DM status, most of these studies used medical records and self-
report. In addition, study subjects were mostly TB patients who were already on TB treatment 
and were recruited from national TB registries and health facilities.  
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Table B-3: Summary of studies assessing the impact of DM on TB treatment outcomes 
Study;                                               
Year;                                         
country 
Study design TB 
Population 
DM diagnosis DM prevalence  
(DM/sample) (%) 




Sub Saharan Africa (SSA)  







FBG ≥ 6.0 mmol/l or 2 
hr blood glucose of ≥ 
11.0 mmol/l. 
197/1250 (16.4)  Death: HIV negative HR: 5.09 (95% 
CI: 2.36 – 11.02)                                   
HIV positive-HR: 2.33 (95% CI: 1.20 
– 4.53) 
Conversion Delay (DMTB vs TB): No 
association 
Age, gender, BMI 
South Asia (SAS) 
(53) Kv 2013; 
2010 – 2011; 
India, Kerela 
Retrospective  TB patients 
with treatment 
cards DOTS 
Medical records, FBG ≥ 
126 mg/dl, RGB ≥ 200 
mg/dl or postprandial 
blood sugar (PPBS) 
667/3116 (24) Combined unfavourable (death, 
default, failure, transfer out) 
outcome: 2.00 ( 0.97 – 4.13) 
Treatment failure: Not significant 
Higher failure among DMTB (p = 
0.04). 
Age group, sex, 
site and type of 
TB, smear result, 
HIV status 
(54) Viswanathan 2014;                                                 
2011; 
South India 
Retrospective TB patient 
with treatment 
cards DOTS 
Medical records of 
biochemical tests 
performed during DOTS 
course.  
96/245 (39.18) Conversion Delay (DMTB vs TB): 
remained positive until end point 
among TBDM vs TB non DM - 3.9 
(1.5;10.6) 
 NR 
Middle East and North Africa (MENA) 
(55) Singla 2006;                                                    
1998-1999 ;                                                    
Saudi Arabia 
Retrospective  Smear positive 
TB patients 
Medical records, FBG≥ 
140 
187/692 (27.02) Resistance: DMTB patients had 
lower prevalence (6.4% vs. 16.0%, P   
0.007) 
Conversion: DBTB patients had 
higher conversion rates within 3 
months (98.9% vs. 94.7%, P   0.013). 
Treatment failure: Favourable 
outcomes comparable between 
groups. 
 NR 
Latin America and Caribbean (LAC) 
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(61) Jiménez-Corona 2013;                 
1995-2010;                                                           
Mexico                                                                           
Prospective Microbiologic
al acid fast 
bacilli patients  
Medical records: FBG≥ 
126 mg/dl or OGTT ≥ 
200 mg/dl 
374/1262 (29.63) Conversion: OR: 1.51 (1.09;2.10) 
Relapse: HR: 1.83 (1.04; 3.23)   
Recurrence  HR: 1.76 (1.11; 2.79)  
Treatment failure:  
OR: 2.93 (1.18; 7.23) 
NR 
(57) Fisher-Hoch 2008;                                 
1996-2002;                                                                              
Mexico and Texas 
Retrospective Texas: 
cultures 
positive               
Mexico: 
sputum  




Death: Texas: OR 2.1(1.1;4.2) 
Mexico: OR 1.8 (1.1;2.9) 
Sputum conversion: Not associated 
Age, gender, 
alcohol and drug 
abuse, HIV, TB 
history 
(56) Dooley 2009; 





DM medication, glucose 
measurement  
42/279 (14) Sputum conversion: DM  vs non DM 
(median 49 versus 39 days, P = 0.09) 
Death: Unadjusted OR: 2.0 (0.74;5.2)                                             
Adjusted OR: 6.5 (1.1;38) 
Treatment failure: non DM 4.1% DM 
6.7%   (P = 0.51) 
HIV, age, weight, 
foreign birth 
(27) Magee 2013; 
2005-2008                                                                      
Peru; 
Prospective TB patients at 
high risk for 
drug-resistant 
TB 
FBG ≥ 7.0 mmol/l,  RBG 
≥ 11.1 mmol/l HbA1c > 
7.0% 
186/1671 (11.13) Not associated  
Treatment failure: Poor outcomes not 
significantly different   
 NR 
East Asia & Pacific (EAP) 
(62) Hongguang 2015; 
2010-2011 
China   
Prospective Registered 
PTB patients  
FBG ≥ 126 mg/dl; 
OGTT≥ 200 mg/dl 
182/1126 (16.16)  Death: OR 5.580 (2.182;14.270) 
Treatment failure: X: OR 6.696 
(2.019;22.200) 




(70) Syed 2013; 
2006 - 2007 
Maylasia 
Retrospective  TB patients 
and suspects  
Medical records 338/1260 (26.83) Treatment failure: No significant 
differences in terms of treatment 
outcomes: (p=0.514) 
Looked at impact 
of DM on TB 
clinical 
presentations 
(58) Mi 2013; 





Smear positive Medical records 189/1589 (11.890)  Death: RR 3.23 (1.08 – 9.63) 
Treatment failure: RR 4.46 (1.96 – 
10.18) 
 NR 







National registry  51/220 (23.18); 
110/437 (25.17) 
 Death: HR 




drinking, smoking,  
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(67) Lee 2014; 






TB cases who 
completed 
treatment  
Medical charts and 
National health insurance 
claims 
DM Cases: 34.0% 
non DM Controls: 
22.7%  
Relapse:  OR 1.96, (1.22–3.15)  NR 
(68) Hsu 2012; 











Two tests >126 mg/dl 




Resistance to INH: 
New on treatment patients: 1.88 
(1.07–3.31); 
Retreatment patients: 6.76 (1.53–
29.98) 
Age, sex  
(65) Chang 2011;                                               






  FBG ≥ 126 mg/dl 
HbAlc ≥ 6.5% 
60/192 (31.25) Resistance: DMTB vs TB:                
5.0% vs 0.8% (p = 0.056) 
Conversion: DMTB vs TB:                   
(2.5 ± 3.0 months vs 1.6 ± 1.4 months 
(p < 0.01) 
Treatment failure: DMTB vs TB:                   
(2.5 ± 3.0 months vs 1.6 ± 1.4 months 
(p < 0.01) 
 NR 
(71) Zhang 2009; 
2008-2009 
China 
Retrospective  Newly 
diagnosed 
PTB patents  
FBG ≥ 126 mg/dl 203/2141 (9.48)  Resistance: DM vs non DM 17.7% vs 
8.4% 
Relapse: DM vs non DM: 20% vs 
5.3% 
NR 
(59) Wang 2009; 
Taiwan 
2003-2006 
Retrospective  Consecutive 
culture-proven 
PTB patients 
Medical records , DM 
history and FBG ≥ 126 
mg/dl confirmatory 
74/217 (34.1)  Death: Type 2 DM (OR 7.6, 95% CI 
1.976–29.083) 
age, sex 
Europe & Central Asia (ECA) 










Physician diagnosis as 
recorded in 
medical records 
86/1366 (6.23) Conversion: HR: 0.93 (0.71–1.23) 
lower rate among MDR-TBDM 
patients but not significant 
Treatment outcomes: RR poor 
outcome: 1.03 (0.93 – 1.14)  
 NR 
(60) Magee 2014;  
2009-2012;                                                        
Georgia 








151/1325 (11.39) Resistance: TB-DM (8.3%) vs TB 
only (9.0%), (p < 0.01) 
Death: During treatment   HR: 1.22 
(0.70;2.12)                                   









Conversion: MDR-TB-DM: 64 (58-
106) vs MDR-TB non DM: 69 (48-
118) 
DM: diabetes mellitus; FBG: fasting blood glucose; OGTT: oral glucose tolerance test; HbA1c: glycated haemoglobin; TB: tuberculosis; PTB: pulmonary tuberculosis; 
ETB: extra pulmonary TB; MDR: multi-drug resistance; BMI: body mass index; NR: Not reported; DOTS: directly observed short course treatment; HR: Hazard 
Ratio; OR: odds ratio; CI: confidence interval 
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Table B-4: WHO definition of tuberculosis treatment outcomes (69) 
 





A pulmonary TB patient with bacteriologically confirmed TB at the 
beginning of treatment who was smear- or culture-negative in the last 





A TB patient who completed treatment without evidence of failure BUT 
with no record to show that sputum smear or culture results in the last 
month of treatment and on at least one previous occasion were negative, 




Relapse Previously treated for TB, were declared cured or treatment completed at 
the end of their most recent course of treatment, and are now diagnosed 
with a recurrent episode of TB (either a true relapse or a new episode of 
TB caused by reinfection) 
 
Treatment failed A TB patient whose sputum smear or culture is positive at month 5 or 
later during treatment. 
 





A TB patient who did not start treatment or whose treatment was 
interrupted for 2 consecutive months or more. 
 
Not evaluated A TB patient for whom no treatment outcome is assigned. This includes 
cases “transferred out” to another treatment unit as well as cases for 





Resistance to at least both isoniazid and rifampicin.  
 
 
B.4.6.1 Failure, relapse and recurrence  
Several studies (58,61,62,65) reported that DM increases the risk of TB relapse, recurrence or 
failure during TB treatment. The proposed reasons for the increased frequency of these 
outcomes among diabetics were that due to impaired immunity, even after TB completion, DM 
patients remain susceptible to reinfection or new infection by new strains after treatment 
completion or being cured. There were studies (27,31,55,64) which however found null 
associations between DM and relapse, recurrence or treatment failure. In particular, two studies 
(27,55) reported that  DM-TB patients had less frequent drug resistance and that they have 
favourable outcomes compared to non-DM TB patients. A possible reason for these null 
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findings could be due to short follow-up period, lack of proper statistical analyses, and not 
accounting for comorbidities such as HIV or competing risk factors (such as retreatment, 
smoking, alcohol and male sex) for these outcomes. Another reason could be due to the fact 
that these studies observed DM-TB patients to be more compliant to their TB medication 
compared to non-DM TB patients (27,55).  
 
B.4.6.2 Sputum conversion 
Sputum conversion, which in most studies referred to the time (usually in days) from treatment 
initiation until the first of two consecutive negative sputum cultures at greater or equal to thirty 
days apart, may also be affected by DM.  There is heterogeneity in the findings regarding the 
impact of DM on time to sputum conversion. Several studies (31,54,58,61,63,65,70) concluded 
that DM delays the time to sputum conversion while others (27,53,66) concluded that DM has 
no significant effect on sputum conversion or that diabetics convert earlier than non-diabetics 
(55,64). Singla et al (55) showed that after three months of TB treatment, more TB patients 
with DM had their sputum converted compared to TB patients without DM (98.9% vs. 94.7%, 
p = 0.013). In these two studies  (55,64), it was also shown that DM-TB patients with well-
managed DM had more favourable TB outcomes than TB patients without DM. This could 
partly explain the reason for early sputum conversion among DM patients than non-DM 
patients.  
 
B.4.6.3 Drug resistance  
There is conflicting evidence for the influence of DM on TB drug resistance. While several 
studies (57,64,65,67,68,71) have reported that DM is associated with resistance, some (27,55) 
have found no association at all. A large proportion of studies (27,65,67,68,71) which found 
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an association between DM and drug resistance were from the Eastern European and Central 
Asian countries where MDR-TB is highly prevalent (72). Although clear mechanisms by which 
DM increases the risk of resistance are not provided, a suggestion is that TB patients remain 
susceptible to re-infection or infection by other strains of TB due to their compromised 
immunity. A possible explanation for the null findings could be due to lack of controlling 
confounding factors and other predictors of resistance such as retreatment (27). Also, as one of 
the studies which found a null association was conducted among TB patients who specifically 
had a high risk of MDR-TB (27), their findings may not be generalizable to the general or other 
specific populations. 
 
B.4.6.4 Death during TB treatment 
More studies (54,58,61,65,70) found positive and significant associations between DM-related 
risk of mortality among TB patients than those (27,55,66) which found non-significant 
associations. Stronger associations were observed after accounting for potential confounders 
such as age, sex and comorbidities such as HIV. The few studies which found non-significant 
associations were retrospective in design and relied on self-report and medical records to 
classify DM. Only one of them used survival analysis. The differences in findings between the 
various studies could partly be explained by methodological differences such as study design, 




B.4.7 Comorbidity  
At the individual level, HIV is a well-known strong risk factor for TB disease and HIV-
associated adverse outcomes (73). Therefore the effect that DM and other risk factors have on 
TB may be modified or masked by HIV comorbidity. In a Ugandan study by Kibirige and 
colleagues, assessing the prevalence of DM among TB patients, the burden of HIV among the 
TB patients was 80%, and commonly recognised risk factors for DM such as high BMI, sex 
and age were found to be statistically insignificant in predicting DM (15). It is possible that in 
such a context HIV may have masked the effect of other predictors of DM. 
 
There are contrasting findings regarding the influence of HIV on DM and on whether it 
modifies the effect of other risk factors. In the same Ugandan study by Kibirige at el,  
HIV was interestingly associated with reduced relative odds of DM  0.17 (95% CI 0.06-0.51, 
p=0.016) (15). The authors proposed that the protective effect was due to cotrimoxazole 
prophylaxis, one of the drugs administered to HIV patients, which has been observed to cause 
hypoglycaemic effects in some patients (15). Faurholt-Jepsen et al in a Tanzanian case control 
study showed that HIV status modified the association between DM and TB (significant 
interaction, p=0.01) (30). 
 
The interaction between TB and DM in HIV patients has been studied with respect to how HIV 
modifies measures of association between DM and TB disease or TB outcomes among HIV 
positive and HIV negative patients. Faurholt-Jepsen et al in a Tanzanian case control study 
showed that HIV status modified the association between DM and TB with a significant 
interaction (p=0.01). A stronger association (odds ratio: 4.2, 95% CI 1.5-11.6) between TB and 
DM was observed among HIV negative patients compared to the association (odds ratio: 0.14, 
95% CI 0.01-1.81) observed among HIV positive patients (30). In another Tanzanian study on 
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the effect of DM on TB outcomes, Faurholt-Jepsen and colleagues showed a higher hazard 
ratio 5.09 (95% CI 2.36 – 11.02) for DM-associated death among HIV negative patients and 
lower hazards 2.33 (95% CI 1.20-4.53) among HIV positive individuals (66). Interestingly, this 
strong association was only observed in the initial hundred days of follow-up with TB treatment 
and not in long term. Although reasons to why this is are not well explained, this potentially 




B.5 Summary and highlights for further research  
Forty five studies which reported the prevalence of DM among TB patients and those which 
assessed the association between DM and TB and the impact of DM on TB outcomes were 
reviewed. The studies were categorised by geographic region which allowed comparison of 
studies by ethnic group, economic setting and the background burden of disease. This review 
highlighted that across all geographic regions and settings, the prevalence of DM among TB 
patients is higher than the expected prevalence of DM in the general population. This 
prevalence is expected to increase especially in low income regions such as SSA.  
 
Current literature suggests that DM impacts every stage of the natural history of TB through 
impaired cell-mediated immunity. In particular, DM increases susceptibility of individuals to 
infection by Mtb and increases the risk of progression to active TB. Furthermore, DM 
contributes to poor TB treatment outcomes: delayed sputum conversion, relapse, and resistance 
to drugs, treatment failure and death on TB treatment.  
 
The common methodological issues which potentially affect the reliability of the estimated 
prevalence of DM among TB patients in the reviewed studies are overestimation of DM 
prevalence due to transient hyperglycaemia in some TB patients, selection bias, and differential 
misclassification of DM cases. Thus, there is a need for methods and analyses techniques to 
account for and address these issues. The clinical condition of TB which induces transient 
chronic hyperglycaemia may lead to over diagnosis of DM and implies the possibility of 
reverse causality between TB and DM. There is therefore a need for DM diagnostic tools which 
will differentiate TB induced hyperglycaemia from hyperglycaemia due to DM. There is also 
a need for studies to investigate the optimal time point and cut-off to diagnose DM among TB 
patients. Also, there are no data on the implications of transient hyperglycaemia on future risk 
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of DM and subsequent TB risk, and impact on TB outcomes, this represents a knowledge gap 
that requires further research. 
 
The prevalence of DM among TB patients also depends on the prevalence of the risk factors 
of DM and other co-morbidities in the studied population. The risk factors of DM among TB 
patients do not seem to be different from those observed in the general population. Increasing 
age, family history of DM, obesity or high BMI and male sex were recognised as significant 
risk factors of DM in most study settings, but were insignificant in some settings. This 
highlights that in order to have effective interventions for DM control, they will need to be 
contextualised to the population characteristics. 
 
Conflicting findings were found among the very few studies which explored the impact of the 
relationship between DM and HIV comorbidity among TB patients. One study found HIV to 
protect against DM and a non-significant interaction between DM and TB in HIV patients, 
while others did find a significant interaction. There are not enough data to explain these 
observations, but this interaction is likely due to the fact that in comparison to DM, HIV is a 
well-established and stronger risk factor for TB disease and mortality at the individual level. A 
much higher HIV-associated risk of TB disease or mortality is thus often observed among non-
diabetics whereas, among HIV negative patients, a very high diabetes-associated risk of TB 
disease or mortality is not observed. It is necessary to increase the number of studies conducted 
in high HIV burden settings to better understand this interaction between DM and TB in HIV 
patients. 
 
Given that DM affects a large proportion of the population and that this burden is rapidly 
increasing, in the presence of an association between DM and TB, the population attributable 
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risk of TB due to DM will likely increase. Therefore the public health importance of this issue 
needs to be highlighted. Health systems will require integrated interventions for prevention, 
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Summary: Current literature suggests that diabetes mellitus (DM) increases the risk of 
tuberculosis (TB) infection and worsens treatment outcomes. Meanwhile, TB remains a public 
health problem in Sub-Saharan Africa with the burden of DM is rapidly increasing. There is 
lack also of recent data on the burden of DM among TB patients in the South African context. 
The aim of the study was to assess the burden of DM and associated risk factors, and the 
prevalence of impaired glucose tolerance (IGT) among TB patients.  
Methods: Between January 2014 and August 2015, a cross sectional study was conducted 
among adult patients presenting consecutively at the Ubuntu TB/HIV clinic. All participants 
had Gene Xpert, microscopy and sputum culture tests to confirm TB status as per the SA TB 
Management Guidelines. Diagnosis of DM was based on oral glucose tolerance test (OGTT) ≥ 
11·1 mmol/L, fasting blood glucose (FBG) ≥ 7·0 mmol/L, glycated haemoglobin (HbA1c) ≥ 
6·5% or self-reported DM. Impaired glucose tolerance was defined 5·7% ≤ HbA1c < 6·5% or 
5·5 ≤ FBG < 7·0 or IGT: 7·7 ≤ OGTT < 11·1 mmol/L. The World Health Organisation STEPS 
Chronic Disease Risk Factor Survey and the SA TB suspect screening questionnaire were used 
to document patients’ characteristics. Bivariate and multivariate including sex-specific 
analyses were performed to determine risk factors associated with DM among these TB 
patients. 
Findings: The prevalence of DM among the TB patients was 39/288 (13·54%; 95% confidence 
interval (CI) 10·03-18·03); DM was previously diagnosed in 11/39 of the DM patients and 
6/11 of these were receiving DM medications. The prevalence of IGT was 139/288 (48·26%; 
95% CI 42·51-54·07%). Common co-existing conditions among the patients were 
hypertension (18·06%; 95% CI 14·01-22·96%) and HIV (64·31%; 95% CI 58·52-69·71%). 
On multivariate analysis, positive family history of DM (odds ratio (OR): 3·20; 95% CI 1·61-
8·83, p=0·025), hypertension (OR 4·49; 95% CI 1·536-13·147; p=0·006) and waist 
 
 
circumference (OR: 1·03; 95% CI 1·00-1·06; p=0·027) were significantly associated with DM. 
In the multivariate model for females, only gestational DM was (p=0·008) was associated with 
DM and in the model for males, hypertension (p=0·024) and the age category > 45 years 
(p=0·005) were associated with DM.  
Interpretation: The high prevalence of IGT highlights that without timely prevention 
interventions the prevalence of DM with further increase. Interventions need to prioritise DM 
screening and management among high risk groups (patients with: hypertension, family history 
of DM, high waist circumference; men with age > 45 years and hypertension; females with 
gestational DM).  
Funding: M.K. was funded by the South African DST/NRF Centre of Excellence in 




C.2. Background  
Although the global incidence of tuberculosis (TB) has shown a 1.65% annual decline over the 
past two decades (1), TB remains a public health challenge in most developing countries such 
as Sub-Saharan Africa (SSA). Factors such as poverty, malnutrition (2), the human 
immunodeficiency virus (HIV) and diabetes mellitus (DM) are known to drive the TB epidemic 
(3).  
An increasing body of evidence suggests that DM is a significant risk factor for TB (4,5). 
Adverse outcomes such as death, relapse and drug resistance, during TB treatment have also 
been associated with DM (6,7). The biological plausibility of the DM-TB association is based 
on hypotheses that DM patients have impaired immune response, dysfunction of alveolar 
macrophages, micronutrient deficiency and pulmonary microangiopathy (8,9). In acute TB 
conditions, TB can also induce chronic hyperglycaemia (8,9), hence complicating this 
association. 
This link has become more significant recently with the burden of DM increasing in low- and 
middle- income countries (LICs and MICs), which continue to suffer a heavy burden of 
infectious diseases (IDs). The burden of DM in Africa was estimated at 19·8 million in 2013 
and is projected to increase to 41·4 million in 2030 (10). These countries that are undergoing 
development processes such as urbanisation, lifestyle, nutritional and epidemiological 
transition. This epidemiological transition is characterised by an increasing burden of non-
communicable disease (NCDs) co-occurring with IDs. Interactions between NCDs and IDs 
have been revealed, sometimes mediated by common risk factors (11).  
Risk factors for DM in the general population are well documented, and include obesity, family 
history of diabetes, poor diet, physical inactivity, increasing age, ethnicity, high blood pressure, 
and gestational diabetes (10). It is however not clear whether the same risk factors apply to TB 
 
 
patients. Some studies have shown increasing age, family history of DM, overweight and 
obesity to be significantly associated with DM among TB patients (12–24), while in other SSA 
regions, overweight among TB patients is not commonly associated with DM. Interaction 
between age and sex (24)  between and BMI and sex are also observed (13). 
South Africa (SA) is listed among the top six countries with a high TB incidence in the world 
and an increasing burden of DM, in 2013 there were between 410 000 and 520 000 new TB 
cases (1) and approximately 2·6 million people living with DM (8,20). The country is also 
undergoing a demographic and epidemiological transition as mentioned above (25). With 
current evidence suggesting that DM increases the risk of TB, this burden of DM is a potential 
threat to current TB control management efforts. Additional to current TB control strategies, 
incorporating the elimination of risk factors for TB may be effective in reducing the TB burden 
at a population level. 
In 2009 a cross-sectional study conducted within predominantly black residential areas 
(including Khayelitsha) in Cape Town estimated the prevalence of DM to be 12·3% and that 
of IGT 11·2% (27). To our knowledge, the only one South African study which assessed the 
prevalence of DM among TB patients reported a 2·1% prevalence in 1980 (12). The current 
study therefore aimed to quantify the current prevalence of DM and IGT, and identify risk 




C.3.1 Study setting  
This study was conducted at Ubuntu Clinic which is an integrated TB/HIV facility and the 
largest TB clinic in Khayelitsha. This township is situated on the outskirts of Cape Town with 
 
 
a population of over 500 000 individuals predominantly constituting of black Africans. In 2011, 
the HIV antenatal prevalence was estimated at 37% and the TB case notification was 1500 per 
100 000 population (28). The high TB incidence in this township is mainly due to the high HIV 
prevalence with a 70% HIV-TB co-infection rate (28).  
 
C.3.2 Study design and sampling 
From January 2014 to August 2015, consecutive patients presenting at Ubuntu Clinic with TB 
symptoms identified by trained clinical research workers and were invited to participate in the 
current study. Patients were eligible if they gave consent, were 18 years or older and had not 
initiated TB chemotherapy. Based on the 16·5% prevalence of DM among TB patients in a 
Ugandan study (29), we manually computed the required sample size to be 207 (n = z2p (1-
p)/d; where d = 0·05, z = 1·96).  
 
C.3.3 Ethical considerations  
All participants included gave written consent and information about the study was reads and 
explained to them in their home language (mainly isiXhosa). Unique participant identifiers 
linked to each participant were used to maintain confidentiality. This study was approved by 
the University of Cape Town Health Research Ethics Committee (HREC REF: 337/2015). 
 
C.3.4 Study procedures  
Confirming TB cases: TB patients were identified through a clinical process as per the South 
African TB Management Guidelines which also adhere to the WHO TB recommendations 
(1,30). Confirmation of TB was made based on a positive test for 1) the sputum smear 
 
 
microscopy; 2) Gene Xpert; 3) Sputum culture; or 4) chest X-rays or clinical presentations 
suggestive of TB (identified by a medical doctor).  
Demographic and socioeconomic characteristics: Demographic information included sex; 
age categorised into ten year intervals; partner status; education level; size of household; 
employment status and income status categorised by the 2011 Census for Khayelistha  (31). 
Diagnosing DM in TB patients: DM and IGT were defined based on the WHO and 
International Diabetes Federation (IDF) recommended definitions (32–34). Blood samples 
were taken to measure fasting blood glucose (FBG) after overnight fasting using, 2 hours oral 
glucose tolerance test (OGTT) and glycosylated haemoglobin (HbA1c); and were analysed at 
a centralised national health laboratory. DM diagnosis was based on self-reported DM, or FBG 
≥7·0 mmol/L; OGTT ≥ 11·1 mmol/L and or HbA1c ≥ 6·5%. IGT was defined as 5·7% ≤ 
HbA1c < 6·5% or 5·5 ≤ FBG < 7·0 and or 7·7 ≤ OGTT < 11·1 mmol/L.  
Chronic diseases: Self-report of other chronic diseases, medication prescription and DM 
symptoms (polydipsia, nocturia or polyuria) were documented. Data on family history of DM, 
gestational DM, hypertension, HIV, and previous TB occurrence were also recorded.  
Anthropometric measurements: Weight and height were measured and body mass index 
(BMI kg/m2) was calculated. The BMI categories were as follows: (underweight: < 18·5, 
normal: 18·5  ≤ BMI < 25, overweight: 25 ≤ BMI < 30, obese: ≥ 30) (35). Waist circumference 
was also measured with the cut off value for high waist circumference (cut off: ≥ 102 cm for 
males and ≥ 88 cm for females) (35). Blood pressure measured and hypertension was diagnosed 
at ≥ 90 Hmmg for diastolic blood pressure or ≥ 140 for systolic blood pressure (36) in addition 
to hypertension medication. 
Lifestyle, diet and behaviour: Smoking status was categorised as ever smoker (past or current 
smokers) or never smoker.  Alcohol intake was categorised as non-drinker or any intake in the 
 
 
past 12 months. Engagement in physical activity and sedentary occupation were also 
documented. Fruit and vegetable intake were categorised as low if patients reported to be 
consuming less than 5 (or 400 g) servings of fruits or vegetables per day (37).   
 
C.4. Statistical analysis 
Medians and inter quartile ranges (IQR) were used to summarise continuous variables and 
categorical variables were summarised using proportions. The Chi-squared and Fisher’s exact 
tests were used to assess associations between categorical variables DM and IGT. To assess 
associations between continuous variables and the categorical variables, the Mann-Whitney 
test was used to compare medians between two groups and the Kruskal-Wallis test to compare 
medians between more than two groups. Logistic regression was performed to identify risk 
factors which were independently associated with either DM or IGT.  
 
A multivariate logistic regression model was manually build to assess independent factors 
associated with DM and IGT. Due to significant differences in characteristics with respect to 
sex, sex-specific models were also build. The log likelihood ratio test was used to compare 
models which were nested. Statistical significance was set at p-value < 0·05.  






Demographic: Of the 288 TB patients included in the analysis, (shown in Table C-1) 167 
(58%) were males, 68·41% of the patients were between the ages 25 and 45 years, the median 
age was 36 years IQR (30-44 years) and the youngest and oldest patients were 18 and 80 years 
respectively. Males were found to be older than females (medians age year: 37 vs 35; p=0·026). 
Socioeconomic: Majority (64%) of the TB patients had secondary level education attainment, 
whilst females were found to have a higher attainment (secondary and tertiary) compared to 
males (p=0·012). Of the patients 50·90% were unemployed and the median monthly income 
was R 2 100 where males earned more (p=0·028) (Table C-1). 
Behavioural: About 38·35% of the TB patients had an alcoholic drink in the past 30 days or 
12 months, the majority of them being males (p<0·001). The prevalence of ever smoking was 
53% and was also higher among males (p<0·001). More females had sedentary occupations 
(p=0·002) and were inactive (p=0·040) (Table C-1).  
Anthropometric: The prevalence of overweight and obesity were 14·71% (95% CI 10·68-
19·93%) and 7·79 (95% CI 4·95-12·07%) respectively. Females had a much higher BMI than 
males (p=0·000) (Table C-1). The prevalence of underweight was 11·69% (95% CI 8·12-
16·55%). More males than females were underweight (16·54% vs 5·10%). Similarly, females 
had higher waist circumference compared to males (p=0·012).  
Comorbidities: The prevalence of hypertension was 18·06% (95% CI 14·01-22·96%); 
36.52% of which were self-reported (68·42% of the self-reported hypertension patients were 
receiving hypertension medication). A larger proportion of the hypertensive patients were 
males (p = 0·000) and HIV co-infection was found to be 64·31% 95% (CI 58·52-69·71%) and 
was significantly higher among females (p < 0·001). Among HIV positive patients, 35·16% 
were on ART and 35·56% of these patients were previous TB cases.  
 
 
Table C-1: Study characteristics of participants stratified by sex 
Variable Females Males Total P-
values  
Continuous variables median (IQR) 
Age (years) 35 (29 – 41) 37 (30 – 45) 288 0.0256 
Income (Rands) 1 800 (900 – 3 000) 2 500 (1 300 – 35000)  0.0242 
Body mass index (kg/m2) 23.89 (21.25 – 26.59 ) 20.41 (18.96 – 22.36) 213 0.0000 
Waist circumference (cm) 82.5 (75 – 88) 77 (74 – 83) 213 0.0012 
Diastolic (mm Hg) 114.5 (107 – 122.5) 119 (109 – 130) 286 0.0022 
Systolic (mm Hg) 74 (69 – 80.5) 75 (69 – 84) 273 0.1957 
HbA1c (%) 5.7 (5.5 – 5.7) 5.9 (5.6 – 6.2) 284 0.2900 
FBG (mmol/L) 4.6 (4.2 – 5) 4.6 (4.2 – 5.2) 286 0.9526 
OGTT (mmol/L) 5.8 (5.1 – 7) 6.3 (5 – 7.4) 255 0.3968 
Categorical variables N (%) 
Age 
< 25 (reference ) 18 (14.88) 15 (8.98) 33 (11.46) 0.097 
25 – 35 45 (37.19) 61 (36.53) 106 (36.81) 
36 – 45 41 (33.88) 50 (29.94) 91 (31.60) 
>45 17 (14.05) 41 (24.55) 58 (20.14) 
Education 
None (reference) 2 (1.17) 11 (6.67) 13 (4.61) 0.012 
Primary 24 (20.51) 54 (32.73) 78 (27.66) 
Secondary 86 (73.50) 96 (58.18) 182 (64.54) 
Tertiary 5 (4.27) 4 (2.42) 9 (3.19) 
Employment 
Unemployed (reference) 67 (58.26) 75 (45.73) 142 (50.90) 0.215 
Employed 42 (36.52) 77 (46.95) 119 (42.65 
Retired/Receiving grants/ 
homemaker 
4 (3.48) 9 (5.49) 13 (4.66) 
Student 2 (1.74) 3 (1.83) 5 (1.79) 
Partner status 
Without partner 79 (67.52) 102 (61.82) 181 (64.18) 0.212 
With partner 23 (19.66) 47 (28.48) 70 (24.82) 
Lost/divorced/separated 15 (12.82) 16 (9.70) 31 (10.99) 
Household size  
0 – 2  (reference) 55 (59.11) 108 (67.08) 163 (59.71) 0.003 
>2 57 (50.89) 53 (32.92) 110 (40.29) 
Income categories 
R 1 – R 1 600 49 (49.49) 44 (33.33) 93 (40.26) 0.028 
R 1 601 – R 3 200 30 (30.30) 50 (37.88) 80 (34.63) 
R 3 201 – R 6 400 13 (13.13) 50 (37.88) 80 (34.63) 
R 6 401 – R 12 800 5 (5.05) 31 (23.48) 44 (19.05) 
R 12 801 or more 2 (2.02) 0 (0.00) 2 (0.87) 
Fruit intake 
More than 5 fruits/day 5 (4.13) 5 (3.05) 10 (3.51) 0.748 
Less than 5 fruits/day 116 (95.87) 159 (96.95) 275 (96.49) 
Vegetable intake 
More than 5 vegetable/day 5 (4.13) 15 (8.98) 20 (6.94) 0.158 
Less than 5 vegetables/day 116 (95.87) 152 (91.02) 268 (93.06) 
Physical activity 
Inactive 109 (94.78) 143 (87.20) 252 (90.32) 0.040 
Active 6 (5.22) 21 (12.80) 27 (9.68) 
Sedentary occupation 
Non sedentary 8 (6.96) 34 (20.73) 42 (15.05) 0.002 
Sedentary 107 (93.04) 130 (79.27) 237 (84.95) 
Alcohol in the past 30 days or 12 months 
No 92 (79.31) 72 (48.00) 164 (61.65)      





No 101 (83.47) 33 (19.76) 134 (46.53) 0.000 
Yes 20 (16.53) 134 (80.24) 154 (53.47) 
BMI categories 
Underweight  ( < 18.5 kg/m2) 5 (5.10) 22 (16.54) 27 (11.69) 0.000 
Normal (18.5 - 24.99 kg/m2) 
(reference) 
56 (57.14) 96 (72.18) 152 (65.80) 
Overweight (25 - 29.99 kg/m2) 26 (26.53) 8 (6.02) 34 (14.72) 
Obese (> 30 kg/m2) 11 (11.22) 7 (5.26) 18 (7.79) 
Waist circumference 
< 102 cm male, < 88 female 68 (75.56) 119 (96.75) 187 (87.79) 0.000 
> 102 cm male, > 88cm female 22 (24.44) 4 (3.25) 26 (12.21) 
Hypertension 
No 108 (89.26) 128 (76.65) 236 (81.94) 0.000 
Yes 13 (10.74) 39 (23.35) 52 (18.06) 
DM symptoms 
No 62 (51.24) 85 (50.90) 147 (51.04) 0.954 
Yes 59 (48.76) 82 (49.10) 141 (48.96) 
DM family history 
No 93 (80.87) 132 (80.49) 225 (80.65) 0.939 
Yes 22 (19.13) 32 (19.51) 54 (19.35) 
HIV Status (self-reported) 
Negative 19 (16.10) 66 (40.00) 85 (30.04) 0.000 
Positive  94 (79.66) 88 (53.33) 182 (64.31) 
Unknown 5 (4.24) 11 (6.67) 16 (5.65) 
Previous TB     
No 68 (69.39) 86 (60.99) 154 (64.44) 0.182 
Yes 30 (30.61) 55 (39.01) 85 (35.56) 
IQR: inter quartile range; HbA1c: Glycated haemoglobin; FBG: fasting blood glucose; OGTT: oral glucose 




The prevalence of DM and IGT 
Out of the 288 TB patients, 39/288 (13·54%; 95% CI 10·03-18·03%) had DM. DM was newly 
diagnosed in 28/39 (72%) of the TB patients. Of the 11/39 (28%) with previously diagnosed 
DM, 6/11 (54·54%) reported to be taking DM medications. Among all the TB patients, the 
HbA1c levels were: median 5·55% (IQR: 5.8-6·15%), ranging between 3·2% and 17·3%. The 
overall HbA1c levels among previously diagnosed DM patients were slightly higher (n=11; 
median HbA1c (%): 11·2; IQR: 7·7-13·3), compared to newly diagnosed DM (n=28; median 
HbA1c (%): 6·6; IQR: 6·5-7·75), p=0.0048. Among previously diagnosed DM patients, those 
on medications had higher HbA1c levels (n = 6, median HbA1c%: 12·15, IQR: 11·2-15·4) 
compared to those not on medications (n = 5, median HbA1c%: 7·7, IQR: 6·9-10·6), p = 
 
 
0·0679. The prevalence of diabetes symptoms nocturia, polydipisia and polyuria were 34·72%, 
35·90% and 37·85% respectively but were not significantly associated with IGT or DM. The 
prevalence of IGT was 139/288 (48·26%; 95% CI 42·51-54·07%). 
On bivariate analysis (Table C-2: ) DM and IGT were significantly associated with alcohol 
consumption in the past 12 months (p=0·013), age categories (p=0·000), education level (p 




Table C-2: Comparison of study characteristics among TB patients with normal glycaemia, 
impaired glucose tolerance (IGT) and diabetes mellitus (DM) 











Continuous variables median (IQR) 
Age (years) 33 (28 – 42 ) 36 (30 – 43) 45 (33 – 57 ) 288 0.029 
Income (Rands)  2 500 (1 200 – 3 500) 2 000 (1 200 – 3 000) 1 600 (1200 - 4000) 231 0.465 
Body mass index 
(kg/m2) 
22.16 (19.58 – 25.08) 20.94 (19.11 - 23.88 ) 23.1 (20.4 - 25.74) 231 0.980 
Waist circumference 
(cm) 
79 (74 – 94) 78 (75 – 84) 84 (76 – 90) 231 0.720 
Diastolic (mm Hg) 75 (69 – 81)5 74 (68 – 82) 80 (74 – 88) 286 0.991 
Systolic (mm Hg) 117 (108 – 127) 116 (106 – 124) 127 (113 – 138) 273 0.164 
HbA1c (%) 5.5 (5.3 – 5.7) 6.0 (5.8 – 6.2) 6.8 (6.5 – 11.2 )  284 0.030 
FBG (mmol/L) 4.3 (4.1 – 4.7) 4.6 (4.3 – 5.1) 5.9 (5.1 – 8.1)   286 0.004 
OGTT (mmol/L) 5.4 (4.85 – 6.2) 6.4 (5.5 – 7.8) 7.6 (6.4 – 12.0) 255 0.081 
Categorical variables N (%) 
Sex  
Female 53 (48.18) 51 (36.69) 17 (43.59) 121 (42.01) 0.185 
Male 57 (51.82) 88 (63.31) 22 (56.41) 167 (57.99) 
Age 
< 25 (reference ) 16 (14.55) 11 (7.91) 6 (15.38) 33 (11.46) 0.000 
25 – 35 49 (44.55) 52 (37.41) 5 (12.82) 106 (36.81) 
36 – 45 30 (27.27) 52 (37.41) 9 (23.08) 91 (31.60) 
>45 15 (12.73) 24 (17.27) 19 (48.72) 58 (20.14) 
Education 
None (reference) 4 (3.67) 7 (5.19) 2 (5.26) 13 (4.61) 0.028 
 Primary 22 (20.18) 40 (29.63) 16 (42.11) 78 (27.66) 
Secondary 76 (69.72) 87 (64.44) 19 (50.00) 182 (64.54) 




56 (52.34) 66 (49.25) 20 (52.63) 142 (50.90) 0.097  
Employed 46 (42.99) 61 (45.52) 12 (31.58) 119 (42.65) 
Retired/Receiving 
grants/ homemaker 
2 (1.87) 6 (4.48) 5 (13.16) 13 (4.66) 




79 (72.48) 84 (62.22) 18 (47.37) 181 (64.18) 0.072 
With partner 22 (20.18) 35 (25.93) 13 (34.21) 70 (24.82) 
Lost/divorced/separate
d 
8 (7.34) 16 (11.85) 7 (18.42) 31 (10.99) 
Number of adults in household 
0 – 2  (reference) 65 (61.90) 78 (58.21) 20 (58.82) 163 (59.71) 0.841 
>2 40 (38.10) 56 (41.79) 14 (41.18) 110 (40.29) 
Income categories 
R 0 (reference) - - - - 0.153  
 R 1 – R 1 600 33 (37.08) 44 (39.64) 16 (51.61) 93 (40.26) 
R 1 601 – R 3 200 31 (34.83) 44 (39.64) 5 (16.13) 80 (34.63) 
R 3 201 – R 6 400 21 (23.60) 16 (14.41) 7 (22.58) 44 (19.05) 
R 6 401 – R 12 800 4 (4.49) 6 (5.41) 2 (6.45) 12 (5.19) 
R 12 801 or more 0 (0.00) 1 (0.90) 1 (3.23) 2 (0.87) 
Alcohol consumption in the past 30 days or 12 months 
No 63 (61.17) 72 (56.25) 29 (82.86) 164 (61.65) 0.013 






No 54 (49.09) 58 (41.73) 22 (56.41) 134 (46.53) 0.211  
 Yes 56 (50.91) 81 (58.27) 17 (43.59) 154 (53.47) 
Fruit intake 
More than 5 fruits/day 1 (1.04) 6 (4.35) 2 (5.26) 9 (3.31) 0.245  
Less than 5 fruits/day 95 (98.96) 132 (95.65) 36 (94.774) 263 (96.69) 
Vegetable intake 
More than 5 
vegetable/day 
4 (4.12) 13 (9.35) 2 (5.13) 19 (6.91) 0.324  
Less than 5 
vegetables/day 
93 (95.88) 126 (90.65) 37 (94.87) 256 (93.09) 
Physical activity 
Inactive 82 (86.32) 122 (91.04) 37 (97.37) 241 (90.26) 0.140 
Active 13 (13.68) 12 (8.96) 1 (2.63) 26 (9.74) 
Sedentary occupation 
Non sedentary 14 (14.74) 22 (16.42) 6 (15.79) 42 (15.73) 0.942  
Sedentary 81 (85.26) 112 (83.58) 32 (84.21) 225 (84.27) 
Hypertension 
No 93 (84.55) 121 (87.05) 22 (56.41) 236 (81.94) 0.000  
Yes 17 (15.45) 18 (12.95) 17 (43.59) 52 (18.06) 
Body mass index 
Underweight (< 18.5 
kg/m2)  
8 (9.41) 18 (15.79) 1 (3.85) 27 (12.00) 0.170 
Normal (18.5 - 24.99 
kg/m2)(reference) 
56 (65.88) 75 (65.79) 17 (65.38) 148 (65.78) 
Overweight (25 - 29.99 
kg/m2) 
16 (18.82) 14 (12.28) 3 (11.54) 33 (14.67) 
Obese (> 30 kg/m2) 5 (5.88) 7 (6.14) 5 (19.23) 17 (7.56) 
Waist circumference 
< 102 cm male or < 88 
cm female 
74 (89.16) 94 (89.52) 19 (76.00) 187 (87.79) 0.159 
 
> 102 cm male or > 88 
cm female 
9 (10.84) 11 (10.48) 6 (24.00) 26 (12.21) 
Diabetes symptoms (Polydipsia, Nocturia or Polyuria) 
No 52 (47.27) 77 (55.40) 18 (46.15) 147 (51.04) 0.358 
Yes 58 (52.73) 62 (44.60) 21 (53.85) 141 (48.96) 
Diabetes family history 
No 75 (78.95) 113 (84.33) 26 (68.42) 214 (80.15) 0.089 
Yes 20 (21.05) 21 (15.67) 12 (31.85) 53 (19.85) 
Gestational diabetes (among females) 
No 50 (98.04) 47 (97.92) 12 (75.00) 109 (94.78) 0.003 
Yes 1 (1.96) 1 (2.08) 4 (25.00) 6 (5.22) 
IQR: inter quartile range; HbA1c: Glycated haemoglobin; FBG: fasting blood glucose; OGTT: oral glucose tolerance test; 




Multivariate Analysis  
The final model Table C-3 for DM included positive family history of DM, hypertension, waist 
circumference and age categories. Of the TB patients, 19·35% (54/279) had a history of DM 
in their families. Among these patients, 38·88% (21/54) had IGT and 22·22% (12/54) had DM 
 
 
where a third (4/12) of the DM was previously diagnosed. TB patients with a positive family 
history of DM had a three-fold increase in the relative odds of DM compared to those without 
family history of DM (OR: 3·203; 95% CI 1·61-8·83, p=0·025). For a 1 cm increase in waist 
circumference, there was a 3% increase in the relative odds of DM (OR: 1·033, 95% CI 1·004-
1·064, p = 0·027).  
The prevalence of hypertension was 18·05% (52/288) and 36·52% (19/52) of this was 
previously known and 68·42% (13/19) of the self-reported hypertension patients were 
receiving hypertension medication. Among the hypertensive patients, 34·61% (18/52) had IGT 
and 32·69% (17/52) had DM. Among the DM-hypertension patients, DM was previously 
diagnosed in 47·06% (8/17) patients. Patients with hypertension had four and a half-fold 
increase in the odds of DM compared to those without hypertension (OR 4·494 95% CI 1·536-
13·147, p = 0·006).  
Age was a confounder for the association between DM and hypertension. Due to significant 
differences in associations between various risk factors (as shown in Table C-1), gender 
specific multivariate models were built. Among males (Table C-4), the age category > 45 years 
(OR 11·049, 95% CI 2·092-58·350, p = 0·005) and hypertension (OR 3·3, 95% CI 1·167-
9·334, p = 0·024) were strongly associated with DM. Among females (Table C-5), only 
gestational DM (OR 14·55, 95% CI 2·033-103·587, p=0·006) was significantly associated with 
DM. Gestational DM was present in 5·22% (6/115) of the females, among them, 66·67% (4/6) 
had DM, of which 50% (2/4) was previously diagnosed, and 16·67% (1/6) had IGT. The 
confidence intervals for these estimates were found to be wide because of the reduced sample 




Table C-3: Multivariate analysis, risk factors associated with DM among TB patients 
Risk factor Odds Ratio Standard 
error 
p-value 95% Confidence Interval 
Age categories     
25 – 35 years 3.489 2.713552 0.108 0.760-16.021 
36 – 45 years 1.482 1.015425 0.566 0.387-5.676 
> 45 years 2.619 1.933768 0.192 0.616-11.133 
Diabetes family history 3.203 1.657989 0.025 * 1.161-8.834 
Waist circumference 1.033 0.0153323 0.027 * 1.004-1.064 
Hypertension 4.494 2.461315 0.006 ** 1.536-13.147 
Significance levels: *0.05; ** 0.01; *** 0.001 
 
Table C-4: Multivariate analysis, risk factors associated with DM among male TB patients 
Risk factors Odds Ratio Standard 
error 
p-values 95%  Confidence 
Interval 
Diabetes family history 2.406 1.489 0.156 0.715-8.093 
Age categories     
25 – 35 years 1.860 2.393 0.629 0.150-23.132 
36 – 45 years  2.893 2.545 0.227 0.516-16.225 
>45 years  11.049 9.381 0.005** 2.092-58.350 
Hypertension 3.300 1.751 0.024* 1.167-9.334 
Significance levels: *0.05; ** 0.01; *** 0.001 
 
Table C-5: Multivariate analysis, risk factors associated with DM among female TB patients 
Risk factors Odds Ratio Standard 
error 
p-value 95% Confidence Interval 
Gestational Diabetes 14.515 14.553 0.008** 2.034-103.587 
Age categories     
       25 – 35 years  3.615 3.250 0.153 0.621-21.060 
       36 – 45 years  2.056 1.744 0.396 0.390-10.841 
       >45 years  5.237 4.540 0.056 0.957-28.64 







The prevalence of DM among TB patients at Ubuntu clinic  
This study aimed to quantify the burden of DM and associated risk factors among TB patients 
in a high TB/HIV setting. To our knowledge, this is first up to date study assessing DM and 
TB in South Africa during this epidemiological era characterised by the high burden of TB/HIV 
and rapidly increasing burden of non-communicable diseases such as DM and hypertension. 
We reported a 13·5% and 48·26% prevalence of DM and IGT.  DM was previously diagnosed 
in 28% of the DM patients and 54·54% were receiving medications of these patients were 
receiving medications. 
The management of DM was poor even among the patients on medication. Unexpectedly there 
were higher glucose levels among those receiving medications compared to those who did not 
(p = 0.0679). In addition to DM complications, this has potential implications for TB outcomes. 
Possible reasons for this may be due to severe TB conditions which may have also induced 
hyperglycaemia (38). Another reason could be that although the patients have prescriptions, 
they may not be taking their medication appropriately or they may not have modified their life 
style as required. This highlights a gap within health care facilities and the need to monitor 
patients on chronic mediation in order to prevent secondary complications.   
Globally, studies assessing the prevalence of DM and associated risk factors among TB patients 
published between 1980 and 2014 reported the prevalence of DM among TB patients ranging 
from 2·1% in South Africa in 1980 to 44% in Kerela, India in 2012 (12–15,18,21,24,29,39). 
The heterogeneity in these findings could be due to differences in socio-demographic and 
economic characteristics of the studied population, differences in methods to diagnose DM, the 




The prevalence of DM in TB patients from South Asian (range: 25·3-44%) (16–19,39) and 
Latin American (range: 14-39 %) (21,22) study populations are high possibly because DM in 
the general populations in high in these regions. In the SSA region, the prevalence ranges 
between 2·1% in South Africa, 1980 to 16·4% in Tanzania in 2012 (12–15,29). Future 
projections suggest that majority of the global increase of DM will be from low income settings 
such as SSA (10). The high prevalence of IGT reported in this study (48%) hints at the 
plausibility of this projected increase. However it also highlights the opportunity for 
interventions to prevent this from happening because IGT is a reversible condition (40).   
 
Risk factors associated with DM among TB patients 
We did not find DM to be significantly associated with any of the socio economic factors. A 
possible reason for this could be because our studied population is relatively homogenous with 
respect to these factors. To explore these associations, populations with variable characteristics 
would have to be included.   
Similar to findings from others studies, hypertension (17), increasing waist circumference 
(13,19) and positive family history of DM (14,16) were significantly associated with DM on 
multivariate analysis. Patients with a diabetes family history had a three-fold increase in the 
odds of diabetes compared to those without (OR: 3·203 95%; CI 1·161-8·834; p=0·025) and 
there was a four and half increase in the odds of DM among those whose with hypertension 
compared to those without hypertension (OR: 4·49; 95% CI 1·536-13·147; p=0.006). For a 
centimetre increase in waist circumference, there was a 3% increase in the relative odds of DM 




In contrast to commonly observed risk factors of DM in the general population, factors such as 
high BMI, sedentary lifestyle, physical inactivity, sex and smoking were not significantly 
associated with DM and pre-DM in our study. Similarly, Kibirige et al 2013 in their study 
found no association between DM  and these mentioned factors (29).  
In our study, normal weight (moderate BMI 18·5-24·99 kg/m2) was very common (64%), it  
therefore makes sense that physical activity, sedentary occupations and high BMI did not play 
a major role in predicting DM or IGT among TB patients. The prevalence of overweight (25-
29·99 kg/m2) and obesity (> 30 kg/m2) were 14·71% (95% CI 10·68-19·93%) and 7·79 (95% 
CI 4·95-12·07%) respectively, given that these patients have TB, this is high. Although 
underweight was higher among males, we did not observe any interaction between sex and the 
different BMI or waist circumference categories. In contrast, Faurholt-Jepsen et al in their 
Tanzanian study assessing predictors of DM among TB patients observed underweight was a 
strong predictor of DM among males (13).  
We suspected that underweight was due to severe DM, HIV or TB itself. However, neither 
BMI nor underweight in particular were significantly associated with either DM or HIV. This 
suggests that among TB patients, BMI which is used as a marker for obesity is not necessarily 
the best indicator for DM, other markers such a waist circumference which approximate 
visceral fat should also be considered. However, it is important to note that 14·71% and 7·79% 
of the patients were overweight and obese respectively, this is high considering that they have 
TB.  
We acknowledge that there are limitations to our study. By the nature of the cross-sectional 
design of the study, temporality between TB and DM could not be ascertained. Among patients 
who had previously diagnosed DM, the time of DM diagnosis was not documented. The TB 
patients included in this study were mostly newly TB diagnosed and not on medication, 
 
 
therefore it is possible that their glucose levels were influenced by the transient hyperglycaemia 
which tends to occur during acute TB conditions (38). Nonetheless, we used the HbA1c test 
which is suggested to possibly overcome this limitation of having transient acute stress induced 
hyperglycaemia as it reflects the average blood glucose level over two to three months (33). 
Patients who were severely ill and could not consent were not included in this study. The 
potential effect of this could be that our study did not include the most severe TB patients who 
may be more likely to have DM given the association between DM and poor TB 
outcomes/prognosis and hence could lead to an under estimation of the DM prevalence. Also, 
we did not distinguish between type 1 and 2 diabetes.  
 
C.7. Conclusion 
The prevalence of DM is likely to increase as indicated by the high prevalence of IGT. 
However, this is also an opportunity to prevent this increase through interventions on 
modifiable risk factors. Furthermore, improved care and follow-up of patients on chronic 
medications is essential to prevent secondary complications. Routine screening of DM among 
TB patients in the identified high risk groups (patients with: hypertension, family history of 
DM, high waist circumference; men with age > 45 years and hypertension; females with 
gestational DM) may be efficient. It is also recommended that health systems manage such 
chronic diseases in an integrated system.  Although overweight and obesity were more 
prevalent than expected among the TB patients, high BMI – a marker for obesity and common 
risk factor for DM in the general population, was not necessarily the best indicator for DM. 
Rather, waist circumference showed a significant association with DM. It is essential to have 
more studies to investigate anthropometric characteristics that could best predict DM among 
TB patients. We have established a high prevalence of DM among TB patients in the South 
African context.  
 
 
Areas of future research in this high TB and HIV burden setting include investigating the causal 
association between DM and TB; the impact of DM on clinical manifestations of TB and TB 
treatment outcomes; and the possible interactions between DM and HIV. Prospective cohort 
and case control study designs may be more appropriate to address these questions. 
Furthermore, it would be essential to conduct dynamic mathematical modelling studies to 
explore the population level contribution of various prevalent TB risk factors including DM, 
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D.1. Protocol for main study 
 
OVERAL RESEARCH OBJECTIVE 
The main aim of this study is to investigate the incremental yield and best screening algorithms for diabetes 
mellitus (DM) and tuberculosis (TB) among a) newly diagnosed TB patients and b) patients attending diabetic 
clinics, respectively. 
Specific aims: 
 To assess the prevalence of DM among TB cases 
 To evaluate the best performing algorithms to diagnose DM in TB cases  
 To measure the prevalence of TB among diabetes patients 
 
BACKGROUND  
TB remains a leading cause of death globally, with an estimated 8.8 million new cases reported every year, 
threatening the goal of global TB elimination by year 2050 (1). Tackling this challenge will require not only 
improvements in diagnostic and treatment services, but identification and reduction of risk factors that increase 
susceptibility for TB. Medical conditions that impair immune function, such as malnutrition, alcoholism or HIV 
co-infection, can increase the likelihood of infection or reactivation of latent TB. Increasing evidence suggests 
that DM is also a significant risk factor for TB. In a recent systematic review, the relative risk for TB in diabetic 
patients was 3.1 (2). The strength of this link was influenced by geographic/ethnic differences, and young people 
were at particularly high risk; in India, DM is thought to be associated with nearly 15% of pulmonary TB cases 
(3). However, these studies had a number of limitations. In particular, very few were carried out in low-income 
countries, with none in Africa, raising uncertainty about the strength of DM-TB association and benefit of bi-
directional screening for DM and TB in these settings with high TB/HIV prevalence and AN increasing burden 
of DM. Practical guidance on when to suspect, and how best to diagnose, diabetes in TB patients, and how to 
confirm or exclude it are lacking. The World Health Organisation recommends HbA1c as a diagnostic test for 
diabetes with a cut-off value of 6.5% (4). However, less clear is the diagnostic value of results below the WHO 
cut-off (there is an argument for population-specific cut-off values). A study conducted on a population of mixed-
ancestry in Cape Town showed that this cut-off value was sub-optimal (erasmus). Furthermore, it is not known 
how the diagnostic performance of the cut-off is affected by acute illness, such as TB. A point of care HbA1c test 
could make diabetes screening more effective and potentially more affordable. A study comparing POC devices 
found that only Afinion and DCA Vantage met the diagnostic performance criteria (6). There are also insufficient 
data on which to base TB screening guidelines for diabetic patients. 
The growing epidemic of diabetes as a threat to TB control 
While 95% of patients with TB live in the low- and middle-income countries, 70% of patients with DM also live 
in these same countries. It is estimated that, worldwide in 2010, there were 285 million people with DM, and the 
number predicted to rise to 438 million by 2030, making DM one of the most common NCDs globally (7). The 
majority of this increase will occur in developing countries where TB remains endemic. Diabetes on this scale is 
likely to pose another threat for global TB control. The potential public health and clinical importance of this 
seems to have been largely ignored until recently. Recent joint consultations by International Union Against 
Tuberculosis and Lung Disease, the World Diabetes Foundation and the World Health Organization emphasised 
the urgent need for research in this area (10). There is also a paucity of data on whether DM is associated with a 
high prevalence of subclinical TB among patients attending diabetic clinics, as observed in HIV-1 co-infected 
persons (13). This has major importance when considering TB screening strategies, with potential for 
amplification by transmission within diabetic clinics and also potentially serious consequences of false-negative 
TB screening. Research is therefore required to develop appropriate and evidence-based guidelines for TB 
screening among persons with DM. 
 
Diabetes, HIV and TB in South Africa and the Western Cape 
South Africa is among the 22 high TB burden countries globally, and also has the highest urban: rural ratio in sub-
Saharan Africa, with 62% of the population being urban dwellers (17). Urbanisation, in addition to rapid 
epidemiological and demographic transition has resulted in a rising burden of NCDs. The global burden of disease 
study demonstrated that in Southern Africa, while HIV and TB rank first and 4th in the top ten causes of morbidity, 
50% of the causes of morbidity are non-communicable; diabetes is ranked 7th. A community survey conducted in 
2008/9 from Cape Town townships showed a DM prevalence of 13.1% (95% CI: 11.0-15.1) (26). 
Mortality rates from NCDs are also increasing; diabetes was the 6th leading causes of mortality in South Africa in 
2010. In the Western Cape, the province within which Cape Town is located, TB and DM are the top 2 causes of 
mortality. Against this background, the prevalence of HIV, the strongest known risk factor for TB, remains high, 




PLAN OF INVESTIGATION 
Setting and study population 
The study will be conducted in Khayelitsha, reputed to be the fastest growing township in South Africa. 
Khayelitsha is located 30km from Cape Town with a population of over 500,000 predominantly black Africans, 
HIV antenatal prevalence of 28% and a TB case-notification rate of >1600/100,000 (27). The largest TB clinic in 
Khayelitsha is Ubuntu clinic. A survey by the Department of Health reported 1187 newly registered TB cases 
were diagnosed at Ubuntu clinic in 2011.  
 
Study design 
DM Screen in TB patients 
We will recruit consecutive TB cases at Ubuntu clinic, prior to initiation of TB treatment. We will record 
demographic, medical and drug history, HIV status and (if positive) date of initiation of ART, regimen, and CD4 
count, as well as clinical, microscopic and radiological characteristics of TB at diagnosis. In addition we will 
document other risk factors for diabetes, such as family history, body mass index (BMI), and waist circumference. 
Before starting TB chemotherapy blood samples will be collected to measure fasting blood glucose and oral 
glucose tolerance test, and HbA1c performed using Afinion, a validated HbA1c Point of care test. Patients will be 
considered to be diabetic if 1) the diagnosis is known at presentation, 2) they are taking oral hypoglycaemic 
therapy and/or insulin or 3) as per case definitions. Previous studies have suggested that it may be more reliable 
to screen for diabetes later in the course of TB treatment rather than at the start (11), because 
inflammation/cytokine stimulation associated with active TB may elevate blood glucose levels resulting in false 
positive diabetes diagnoses if tests are performed too early. We will, therefore, repeat fasting blood glucose and 
HbA1c tests after 2 months of TB treatment. Patients with a new diagnosis will be referred to the DM clinic for 
standard care. HIV testing is offered routinely to all patients with TB.  
TB screen in diabetic patients 
We will recruit consecutive diabetes patients presenting to the primary care diabetes clinic at Khayelitsha day 
hospital. A TB screen will be performed as per case definition. We will also record demographic, medical and 





Subclinical TB disease Smear microscopy positive for acid fast bacilli 
  Isolation  
 








 Accuracy of established intensified TB case-finding strategies among diabetics 
 Prevalence of diabetes in TB patients 
 Prevalence of TB in diabetics, including subclinical TB disease 
 Effect of diabetes on TB clinical presentation (number and duration of pulmonary TB symptoms, TB sputum 
smear and microscopy results, CXR findings, non-pulmonary manifestation of disease) and/or treatment 
outcomes of TB (2 month TB sputum clearance, completion and cure rates) 
 
Sample size and power calculations 
Assuming a DM prevalence of 24% in TB patients (based on a TB/DM risk ratio of 2 and DM prevalence in the 
general population of 12%), in order to have 80% statistical power and a screening tool sensitivity of 60%, a 
sample size of 1537 TB cases is required in Malawi and South Africa respectively. This sample size will provide 
sufficient power to define and investigate different potential DM screening algorithms in TB patients. 
 
For the TB prevalence in DM patients study, a sample size of 457 diabetic patients is required, assuming TB 
prevalence of 5% and at 2% precision. 
 
Statistical analysis plan  
The prevalence of diabetes and TB will be based on the respective gold standard diagnostic tests. We will calculate 
the sensitivity, specificity, positive and negative predictive values of the screening tools to diagnose DM in TB 
cases, and TB in DM patients, using OGTT and TB culture gold standards, respectively. Among TB cases, risk 
factors associated with DM will be analysed using logistic regression. The model will be built manually with 
nested models compared using the likelihood ratio test. The Akaike’s Information Criterion (AIC) will be used to 
compare non-nested models with a significantly lower AIC (>10%) indicating an improved model. In addition, 
outlying and influential observations will be identified and potential effect modification assessed using interaction 
variables. 
 
To develop and evaluate a DM screening algorithm in TB cases, based on symptom screening, HIV status, ART, 
age, sex, BMI, waist circumference, and DM family history. Multivariable logistic regression analysis will then 
be performed to develop diagnostic models for DM using OGTT findings as the gold standard. A reduced 
clinical model without additional investigations will first be derived. These tests will then be added singly to the 
reduced clinical model and then simultaneously to explore the added predictive value of a single test and of 
combined tests, respectively. The ability of a multivariable model to discriminate persons with DM from those 
without will be assessed using Receiver Operator Characteristic curve and Area Under the Curve analysis. 
Significance testing will be done using a combination of two-sided p-values (p<0.05) and 95% confidence 
intervals. All data will be analysed using STATA 12.0 (StataCorp, College Station, TX, USA) 
 
Ethical considerations 
This study has received ethics approval from the University of Cape Town Human Ethics committee (HREC Ref: 
403/2011). A written consent will be obtained from all participants who will be given detailed explanation of the 
study. An information sheet will be available both in English and Xhosa. 
 
Anticipated overall outputs and impacts  
This study performed at such an important time, with respect to the emerging diabetes epidemic in sub-Saharan 
Africa, will provide an invaluable set of data to document the strength of association between diabetes and TB 
and its clinical/public health impact. Data of this quality does not exist in the current literature on the link between 
TB and diabetes in sub-Sahara Africa; hence we expect this study to produce a series of high quality publications. 
Additionally, the study is designed to raise further research questions and provide some of the ground work 
needed, for example to determine 1) optimal screening models 2) whether diabetes influences recurrence of TB 
or anti-tuberculosis drug resistance 3) the need to develop randomised controlled trials of efficacy of interventions, 
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D.5. List of variables  
 
Table D-1: List of study variables 
Variables Variable type Code number:= Category Name in STATA 
Main outcome: Dependent variables 
Impaired glucose 
tolerance (IGT)  
Categorical 0:= Normal 
1:= Pre-diabetic ( 5.7% ≤ HbA1c < 6.5% or 5.5 ≤ 
FBG < 7.0 or 7.7 ≤ OGTT < 11.1 mmol/dl) 
2:= Diabetic ( FBG > 7.1 mmol/dl or OGTT > 





Binary 0:= No diabetes 
1:= Diabetic ( FBG > 7.1 mmol/dl or OGTT > 
11.1 mmol/dl or HbA1c > 6.5% or self-report and 
medication prescription) 
combinedDM 
Risk factors: Independent Variables 
Sex Binary 0:= Female 
1:= Male 
Sex 
Age Continuous and 
categorical 
Continuous;  
0:= < 25  
1:= 26 - 35  
2:= 36 - 45  
3:= 46 - 55  
4:= > 55  






0:= No education 
1:= primary  









1:= Employed  






Partner status Categorical 
 
0:= Without partner  




persons older than 




0:= Two or less 
1:= More than two 
adultsInHouseCat 
Average income  Categorical 
 
0:= < R 1 = 0  
1:= R 1 - R 1 600 = 1 
2:= R 1 601 - R 3 200 = 2 
3:= R 3 201 - R 6 400 = 3 
4:= R 6 400 - R 12 800  =  4 








the past 12 months 
Binary 0:= No 
1:= Yes 
alc12mnth30day  
Ever smoker Binary 0:= No 
1:= Yes (past and current) 
everSmk 
Fruit intake Binary 0:= 5 or more servings/day 
1:= less than 5 servings/day 
lowFruitIntake 
Vegetable intake Binary 0:= 5 or more servings/day 
1:= less than 5 servings/day 
lowVegIntake 
Physical activity Binary 0:= inactive  






Binary 0:= non-sedentary (occupation involving vigorous 
or moderate activity) 
1:= sedentary  
sendOccu 
Body mass index Binary continuous;  
0:= Underweight ( < 18.5 kg/m2) 
1:= Normal (18.5 - 24.99 kg/m2) 
2:= Overweight (25 - 29.99 kg/m2) 





Continuous Continuous Waistcircumference 
Male waist 
circumference  
Binary  0:= less than 102 cm 




Binary 0:= less than 88 cm 
1:= 88 cm and more 
centObesFema 
Hypertension  Binary 0:= no hypertension 
1:= Hypertensive (diastolic > 90 mmHg or 
systolic > 140 mmHg or self-report and 




Binary 0:= No 










Binary  0:= No 
1:= Yes 
DMSymptoms 
Nocturia Binary  0:= No 
1:= Yes 
Nocturia 
Polydipsia Binary  0:= No 
1:= Yes 
Polydipsia 










Binary  0:= No 
1:= Yes 
gestationalDiabetes 






Binary  0:= No 
1:= Yes 
ARV 
Previous TB Binary  0:= No 
1:= Yes 
previoustb 

















D.6. Detailed statistical analysis 
 








At the time of data extraction, 381 screened TB suspects had complete data on at least sex and 
age. Of these 381 TB suspects, 301 had their TB status confirmed as per case definitions and 
288 of them had their DM status ascertained. Therefore, we included 288 patients in the 
analysis.   
 
D.6.1 Statistical analysis and model building 
 
Univariate/Descriptive analysis: None of the numerical continuous variables were normally 
distributed. Medians and inter quartile ranges (IQR) were used to summaries continuous 
variables. Categorical variables were summarised using proportions. 
Bivariate analysis: The chi-squared test was performed to assess associations between 
categorical variables and the outcome variables (DM and pre-DM), the Fishers exact for cells 
with less than five observations. To assess associations between continuous variables and the 
categorical variables, the Mann-Whitney test was used to compare medians between two 
groups and the Kruskal-Wallis to compare medians between more than two groups. Logistic 
381 TB suspects 
301 confirmed TB cases 
288 DM status ascertained  
80 TB results not complete 
13 had no DM outcomes  
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regression was performed to identify factors which were independently associated with either 
DM or pre-DM. 
Multivariate analysis: Multivariate analysis was performed was performed to manually build 
a model of independent predictors of DM and pre-DM. The log likelihood ratio test was used 
to compare models which were nested. This test measures the difference in deviance between 
two nested models to assess the extent to which an additional risk factor improves the model 
fit.  For model selection, statistical significance was based on p-value < 0.05 and a higher chi-
squared statistic value of the log likelihood ratio test and statistical significance of each risk 
factor was based on p-value < 0.05.  
Model Building: 
The second objective of this study was to determine risk factors associated with DM. To obtain 
such a set of variables, several statistical variable selection methods are suggested: the forward, 
backward and stepwise variable selection procedures. We used the forward selection procedure 
because it allows us to first screen the variable which are potential model candidates, it also 
allows us to use clinical knowledge/judgement on as to which variables to include as exposure 
factors and confounders. Lastly, it is a fairly straight forward method. 
Based on the literature, from studies conducted in the SSA region, the following risk factors 
were  have been identified as being associated with DM among TB patients: male sex 
increasing age, obesity, BMI, waist circumference, sedentary lifestyle, a positive family history 
of DM, and gestational diabetes. These factors were considered in the multivariate analysis to 
build a model of risk factors independently associated with DM among TB patients. In addition, 




Based on suggestions from the literature, we considered age and sex to be potential confounders 
(particularity for the association between hypertension and DM). We assessed whether these 
variables confound the association between DM and hypertension and found age to be a 
confounder (it met the 3 conditions for a variable to be a confounder: 1) confounder associated 
with outcome (DM); 2) confounder associated with exposure (hypertension) among those 
without the outcome (non-DM) and 3) confounder is not in the causal pathway (not a mediator) 
between exposure (hypertension) and outcome (DM). 
Forward selection: 
 We first include a model with just a constant (baseline). We then screened the next 
variable that would improve the model based on the lowest AIC for non-nested 
models, and higher Chi-squared value and lowest p-value for log likelihood ratio 
test for nested model.   
 The first variable added to the baseline model was age categories (the confounder) 
 One at a time we added other variables and assessed which improved the model 
until saturation – giving the best model 
 In this best model, we assessed the presence of effect modification between the 
confounder and other risk factor variables. 
 The best model for DM and other risk factors included age categories, hypertension, 
DM family history, waist circumference.   
Effect modification: 
 We then tested whether sex modified the effect of waist circumference (i.e. if the 
effect of waist circumference on DM depended on either being male or female) by 
adding an interaction term (the product of sex and waist circumference in the 
logistic regression model). The p-value for the coefficient of this term was not 
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significant (p>0.05) and the confidence interval included the null. Therefore, 
based on this data, we concluded that there was no interaction between sex and 
waist circumference.   
 Model checking was then performed 
 
Model checking: To the check the validity of each models, we need to assess:  
1) The form of the linear component of the model: We plot a scatter plot of deviance and 
Pearson residuals against the linear predictor – for a good model, positive responses 
(DM cases) should tend close towards the horizontal line (= 0) as linear predictors gets 
larger, the negative response (non DM) should tend away from the residuals as the 
linear predictor increases. Also plot residuals against observations, for a good model 
we expect a random scatter.  
2) For binary response models, we check the adequacy of the link (transformation) 
function: The logit transformation function is considered to be an appropriate for the 
binary response variables.  
3) The presence and influence of influential observations: outliers were identified by 
standard residuals greater than +2 or less than -2. Influential observations were 
identified using the hi which measures how far the covariate pattern lies from the 
average covariate pattern. 
Multicollinearity: We assessed the presence of multicollinearity using the variance inflation 
factor (VIF) and Pearson correlations. VIF >>> 10 or Pearson correlations > 0.9 indicate the 





D.6.2 Building a multivariate model for diabetes mellitus 
 
Table D-2: Forward selection model building - a model for risk factors associated with DM 
    Log likelihood ratio test 




A - Constant 279 -111.0438 224.0875 - - 
B A Sex 288 -114.185 232.37 0.05 0.8304 
C A ageCat0 ageCat2 ageCat3 288 -101.8414 211.6829 24.73 0.0000 
D A ageAtConsentr 288 -103.7484 211.4968 20.92 0.0000 
E A incomeCats2 incomeCats3 
incomeCats4 incomeCats5 
288 -110.5919 233.1838 6.96 0.1378 
F A combineIncome  231 -90.99918 185.9984 0.16 0.6851 
G A PatnerStatus1 PatnerStatus2 288 -111.6024 229.2047 5.21 0.0739 
H A alc12mnth30day 288 -114.0985 232.1969 0.22 0.6398 
I A everSmk  288 -113.3244 230.6488 1.77 0.1837 
J A PAstatus  279 -109.4021 222.8042 3.28 0.0700 
K A BMIcat0 BMIcat2 BMIcat3  231 -78.31218 164.6244 5.92 0.1157 
L A BMI  231 -80.29389 164.5878 1.95 0.1621 
M A Waistcircumference  213 -73.84245 151.6849 6.38 0.0115 
N A highWC  213 -75.49233 154.9847 3.08 0.0793 
O A DiabetesFamilyHistory 279 -109.1486 222.2971 3.79 0.0515 
P A gestationalDiabetes 276 -106.0325 216.0649 9.14 0.0025 
Q A HIVstate 288 -113.7722 231.5444 0.87 0.3505 
R A educationLevel1 educationLevel2 
educationLevel3 
288 -111.9097 231.8194 4.60 0.2038 
S A DMSymptoms  288 -113.9923 231.9845 0.43 0.5113 
T A lowFruitIntake 285 -111.7346 227.4692 0.36 0.5512 
U A lowVegIntake  288 -114.0837 232.1674 0.25 0.6182 
V A combHPTN  288 -106.0054 216.0107 16.41 0.0001 
W A sendOccu 279 -111.0345 226.0691 0.02 0.8921 
Y A pevTB 239 -88.32216 180.6443 0.02 0.8965 
Z A employmentStatus 279 -110.7042 225.4085 0.68 0.4099 
Model C: ageCat0 + ageCat2 + ageCat3 + ___ 
B2 C Sex 288 -101.5644 213.1288 0.55 0.4567 
C2 C incomeCats2 incomeCats3 
incomeCats4 incomeCats5 
288 -99.64897 215.2979 4.38 0.3564 
D2 C PatnerStatus1 PatnerStatus2 288 -101.4903 214.9806 0.70 0.7039 
E2 C alc12mnth30day 288 -101.712 213.4241 0.26 0.6109 
F2 C everSmk 288 -100.7003 211.4006 2.28 0.1309 
G2 C PAstatus  279 -98.64378 207.2876 1.82 0.1772 
H2 C BMIcat0 BMIcat2 BMIcat3 231 -72.23391 158.4678 4.78 0.1889 
I2 C BMI  231 -73.45768 156.9154 2.33 0.1270 
J2 C Waistcircumference 213 -69.04241 148.0848 6.97 0.0083 
K2 C highWC 213 -70.58404 151.1681 3.88 0.0488 
L2 C DiabetesFamilyHistory 279 -96.05849 202.117 6.99 0.0082 
M2 C gestationalDiabetes  276 -94.73974 199.4795 8.51 0.0035 
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N2 C HIVstate 288 -101.7586 213.5173 0.17 0.6840 
O2 C educationLevel1 educationLevel2 
educationLevel3 
288 -101.7128 217.4257 0.26 0.9679 
P2 C DMSymptoms  288 -101.7502 213.5004 0.18 0.6692 
Q2 C lowFruitIntake  285 -98.23264 206.4653 0.86 0.3527 
R 2 C lowVegIntake  288 -101.8025 213.6051 0.08 0.7803 
S2 C combHPTN 288 -98.76954 207.5391 6.14 0.0132 
T2 C sendOccu  279 -99.55387 209.1077 0.00 0.9789 
U2 C prevTB 239 -80.3762 170.7524 0.23 0.6332 
W2 C employmentStatus 279 -99.40419 208.8084 0.07 0.7891 
Model L2: ageCat0 ageCat2 ageCat3 + DiabetesFamilyHistory + ___ 
B3 L2 Sex 279 -95.78425 203.5685 0.55 0.4589 
C3 L2 incomeCats2 incomeCats3 
incomeCats4 incomeCats5 
279 -94.31157 206.6231 3.49 0.4788 
D3 L2 PatnerStatus1 PatnerStatus2 279 -95.59153 205.1831 0.93 0.6269 
E3 L2 alc12mnth30day 279 -95.99308 203.9862 0.13 0.7176 
F3 L2 everSmk 279 -94.44835 200.8967 3.22 0.0727 
G3 L2 PAstatus  278 -94.67994 201.3599 2.169 0.1012 
H3 L2 BMIcat0 BMIcat2 BMIcat3 226 -65.86258 147.7252 5.46 0.1410 
I3 L2 BMI  226 -67.43162 146.8632 2.32 0.1275 
J3 L2 Waistcircumference  210 -63.90952 139.819 5.99 0.0144 
N3 L2 HIVstate 279 -96.05126 204.1025 0.01 0.9043 
O3 L2 educationLevel1 educationLevel2 
educationLevel3 
279 -95.80296 207.6059 0.51 0.9165 
P3 L2 DMSymptoms  279 -96.04526 204.0905 0.03 0.8708 
Q3 L2 lowFriuitIntake 276 -92.31133 196.6227 0.79 0.3752 
R 3 L2 lowVegIntake 279 -95.61332 203.2266 0.89 0.3454 
S3 L2 combHPTN 279 -93.72197 199.4439 4.67 0.0306 
T3 L2 sendOccu 278 -96.00177 204.0035 0.04 0.8351 
U3 L2  prevTB 234 -75.09717 162.1943 0.14 0.7084 
W3  L2 employmentStatus 276 -95.59099 203.182 0.23 0.6336 
Model J3: ageCat0 ageCat2 ageCat3 + DiabetesFamilyHistory + Waistcircumference___ 
B4 J3 Sex 210 -63.35181 140.7036 1.04 0.3088 
C4 J3 incomeCats2 incomeCats3 
incomeCats4 incomeCats5 
202 -62.40911 142.8182 3.00 0.3915 
D4 J3 PatnerStatus1 PatnerStatus2 210 -63.73752 143.475 0.34 0.8420 
E4 J3 alc12mnth30day 210 -63.73143 141.4629 0.36 0.5506 
F4 J3 everSmk 210 -63.10808 140.2162 1.60 0.2055 
H4 J3 PAstatus  207 -58.81812 135.6362 1.45 0.2288 
G4 J3 BMIcat0 BMIcat2 BMIcat3 209   -63.14545  140.2909   1.53 0.6743 
I4 J3 BMI  207 -59.47065 132.9413 0.23 0.6317 
K4 J3 HIVstate 210 -63.79241 141.5848 0.23 0.6284 
L4 J3 educationLevel1 educationLevel2 
educationLevel3 
210 -63.2099 144.4198 1.40 0.7057 
M4 J3 DMSymptoms  210 -63.73157 141.4631 0.36 0.5508 
N4 J3 lowFriuitIntake 205 -60.32836 132.6567 perfect prediction 
O4 J3 lowVegIntake 210 -63.86784 141.7357 0.08 0.7728 
P4 J3 combHPTN 210 -60.21241 134.4248 7.39 0.0065 
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Q4 J3 sendOccu 209 -63.80134 141.6027 0.14 0.7117 
R 4 J3 prevTB  234 -75.09717 162.1943  0.14 0.7084 
T4 J3 employmentStatus  276 -95.59099 203.182 0.23 0.6336 
ageCat0 ageCat2 ageCat3 + DiabetesFamilyHistory + Waistcircumference + combHPTN___ 
B5 P4 Sex 210 -58.87778 133.7556 2.67 0.1023 
C5 P4 incomeCats2 incomeCats3 
incomeCats4 incomeCats5 
202 -57.84402 135.688 4.74 0.1921 
D5 P4 PatnerStatus1 PatnerStatus2 210 -59.74844 137.4969 0.93 0.6288 
E5 P4 alc12mnth30day  210 -59.67237 135.3447 1.08 0.2987 
F5 P4  everSmk 210 -58.828 133.656 2.77 0.0961 
G5 P4 PAstatus 209 -59.45269 134.9054 1.45 0.2286 
H5 P4 BMIcat0 BMIcat2 BMIcat3 207 -55.0837 130.1674 1.51 0.6793 
I5 P4 BMI  207 -55.77546  127.5509 0.13 0.7191 
K5 P4 HIVstate 210 -59.6979 135.3958 1.03 0.3104 
L5 P4 educationLevel1 educationLevel2 
educationLevel3 
210 -59.59552 139.191 1.23 0.7449 
M5 P4 DMSymptoms  210 -60.05538 136.1108 0.31 0.5752 
N5 P4 lowFriuitIntake 205 -57.27095 128.5419 perfect prediction 
O5 P4 lowVegIntake  210 -60.11968 136.2394 0.19 0.6667 
Q5 P4 sendOccu  209 -60.13025 136.2605 0.09 0.7588 
R 5 P4 employmentStatus  207 -58.80236 133.6047 2.41 0.1204 





Figure D-2: Goodness of fit output for final DM mode (model P4) 
 
 
D.6.3 Sex-specific multivariate models for DM 
 
Due to significant differences in associations between various risk factors (age, income, BMI, 
WC, hypertension, education, physical activity status, sedentary occupation, alcohol 
consumption and smoking, HIV status) and DM with respect to gender, we performed gender 
specific models. This was done by restricting/stratifying the multivariate analysis by gender 
groups (male and female). The disadvantage of stratifying the data would be loss of power due 







D.6.4.1 Building a multivariate model of diabetes mellitus among males 
 
Table D-3: Forward selection model building - a model for risk factors associated with DM 
among males  
    Log likelihood ratio test 
Model 
 
VS Variables included N 
Log 





Constant 164 -64.64772 131.2954 
 
 
C A ageCat0 ageCat2 ageCat3 167 -55.05246 118.1049 20.05 0.0002 
D A combHPTN 167 -57.39321 118.7864 15.36 0.0001 
E 
A incomeCats2 incomeCats3 
incomeCats4   incomeCats5 167 -61.86833 131.7367 6.41 0.0931 
F A combineIncome 132 -52.51328 109.0266 0.13 0.7221 
G A PatnerStatus1 PatnerStatus2 167 -64.09002 134.18 1.97 0.3732 
H A alc12mnth30day 167 -64.97758 133.9552 0.20 0.6579 
I A everSmk 167 -65.00739 134.0148 0.14 0.7118 
J 
A 
PAstatus 143 -61.39319 124.7864 males only 
 
K A BMIcat0 BMIcat2 BMIcat3 133 -39.39874 86.79747 6.35 0.0958 
L A BMI 133 -41.87956 87.75912 1.39 0.2389 
M A Waistcircumference 123 -37.58128 79.16257 3.48 0.0621 
N A highWC 123 -37.10551 78.21103 4.43 0.0353 
O A DiabetesFamilyHistory 164 -64.19445 132.3889 0.91 0.3410 
P A gestationalDiabetes 161 -64.21129 130.4226 females only 
Q A HIVstate 167 -64.15325 132.3065 1.84 0.1744 
R 
A educationLevel1 educationLevel2 
educationLevel3 161 -61.35592 128.7118 6.87 0.0322 
S A DMSymptoms 167 -65.0081 134.0162 0.14 0.7132 
T A lowFruitIntake 164 -62.65126 129.3025 0.21 0.6466 
U A lowVegIntake 167 -64.71797 133.4359 0.72 0.3977 
W A sendOccu 164 -64.2241 132.4482 0.85 0.3573 
Model D: combHPTN +___ 
A1 D ageCat0 ageCat2 ageCat3 167 -52.13444 114.2689 10.52 0.0146 
B1 
D incomeCats2 incomeCats3 
incomeCats4 incomeCats5 167 -54.25403 118.5081 6.28 0.0988 
C1 D combineIncome 132 -43.86678 93.51037 0.22 0.6366 
E1 D PatnerStatus1 PatnerStatus2 167 -57.09184 122.1837 0.60 0.7398 
F1 D alc12mnth30day 167 -57.05622 120.1124 0.67 0.4117 
I1 D everSmk 167 -57.02835 120.0567 0.73 0.3930 
H1 D PAstatus 143 -54.43682 112.8736 -5.47 . 
J1 D BMIcat0 BMIcat2 BMIcat3 133 -27.70433 65.40865 4.60 0.2033 
K1 D BMI 133 -29.38949 64.77898 1.23 0.2668 
L1 D Waistcircumference 123 -28.01645 62.03289 1.47 0.2250 
M1 D highWC 123 -27.1682 60.33639 3.17 0.0751 
N1 D DiabetesFamilyHistory 164 -56.97464 119.9493 16.20 0.0003 
P1 D HIVstate 167 -57.26089 120.5218 0.26 0.6070 
Q1 
D educationLevel1 educationLevel2 
educationLevel3 161 -54.93225 117.8645 4.63 0.0989 
R 1 D Dmsypmtoms 167 -57.32472 120.6494 0.14 0.7113 
S1 D lowFruitIntake 164 -55.34472 116.6894 0.28 0.5981 
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T1 D lowVegIntake 167 -57.08653 120.1731 0.61 0.4335 
U1 D sendOccu 164 -56.8478 119.6956 0.65 0.4208 
Model N1: combHPTN + DiabetesFamilyHistory  + ___ 
A2 N1 ageCat0 ageCat2 ageCat3 164 -51.08066 114.1613 11.79 0.0081 
B2 
N1 incomeCats2 incomeCats3 
incomeCats4 incomeCats5 164 -53.93108 119.8622 6.09 0.1074 
C2 N1 combineIncome 132 -42.63591 93.27181 0.02 0.9015 
E2 N1 PatnerStatus1 PatnerStatus2 164 -56.63782 123.2756 0.67 0.7140 
F2 N1 alc12mnth30day 164 -56.61294 121.2259 0.72 0.3950 
I2 N1 everSmk 164 -56.50702 121.014 0.94 0.3335 
H2 N1 Pastatus 143 -54.1239 114.2478 -5.70 . 
J2 N1 BMIcat0 BMIcat2 BMIcat3 132 -27.04553 66.09107 4.69 0.1958 
K2 N1 BMI 132 -28.8565 65.71301 1.07 0.3010 
L2 N1 Waistcircumference 123 -27.45415 62.9083 1.10 0.2945 
M2 N1 highWC 123 -26.63896 61.27793 2.73 0.0985 
P2 N1 HIVstate 164 -56.87238 121.7448 0.20 0.6511 
Q2 
N1 educationLevel1 educationLevel2 
educationLevel3 160 -54.21733 118.4347 5.51 0.0635 
R 2 N1 DMSymptoms 164 -56.86547 121.7309 0.22 0.6403 
S2 N1 lowFruitIntake 161 -54.47715 116.9543 1.17 0.2796 
T2 N1 lowVegIntake 164 -56.75666 121.5133 0.44 0.5091 
U2 N1 sendOccu 164 -56.69792 121.3958 0.55 0.4569 
Model A2: combHPTN + DiabetesFamilyHistory  + ageCat0 ageCat2 ageCat3 + __ 
C4 A2  combineIncome 132 -38.22499 90.44999 0.01 0.9112 
E4 A2  PatnerStatus1 PatnerStatus2 164 -50.83573 117.6715 0.49 0.7828 
F4 A2  alc12mnth30day 164 -50.85675 115.7135 0.45 0.5034 
I4 A2  everSmk 164 -50.84507 115.6901 0.47 0.4925 
H4 A2  PAstatus 143 -54.1239 114.2478 6.09 0.1075 
J4 A2  BMIcat0 BMIcat2 BMIcat3 132 -25.55617 69.11233 3.83 0.2799 
K4 A2  BMI 132 -27.091 68.182 0.77 0.3818 
L4 A2  Waistcircumference 123 -27.19478 68.38955 0.86 0.3531 
M4 A2  highWC 123 -26.4719 66.9438 2.31 0.1287 
P4 A2  HIVstate 164 -51.0129 116.0258 0.14 0.7128 
Q4 A2  educationLevel1 educationLevel2 164 -54.21733 120.4347 1.42 0.6997 
R 4 A2  DMSymptoms 164 -50.80864 115.6173 0.54 0.4608 
S4 A2  lowVegIntake 161 -47.59236 109.1847 0.83 0.3633 
T4 A2  lowFruitIntake 164 -50.73496 115.4699 0.69 0.4057 











D.6.4.2 Building a multivariate model of diabetes mellitus among females 
 
Table D-4: Forward selection model building - a model for risk factors associated with DM 
among females  
    Log likelihood ratio test 
Model  
VS 
Variables included N  
Log 
likelihood AIC χ2 p-value 
A - constant 115 -46.38891 94.77782 - - 
B A combHPTN 121 -47.73167 99.46334 2.76 0.0969 
C A ageCat0 ageCat2 ageCat3 121 -45.06288 98.12577 8.09 0.0441 
D A sendOccu 115 -44.87114 93.74228 3.04 0.0815 
E 
A incomeCats2 incomeCats3 
incomeCats4 incomeCats5 121 -48.08311 106.1662 2.12 0.7138 
F A combineIncome 99 -38.221 80.442 0.56 0.4562 
G A PatnerStatus1 PatnerStatus2 121 -46.49119 98.98238 5.24 0.0729 
H A alc12mnth30day 121 -48.22959 100.4592 1.76 0.1847 
J A PAstatus 115 -46.36982 96.73965 0.04 0.8451 
K A BMIcat0 BMIcat2 BMIcat3 98 -36.95419 81.90839 2.81 0.4225 
L A BMI 98 -38.17312 80.34624 0.37 0.5441 
M A Waistcircumference 90 -35.92221 75.84441 2.49 0.1148 
N A highWC 90 -37.00786 78.01572 0.32 0.5744 
O A DiabetesFamilyHistory 115 -44.63309 93.26618 3.51 0.0609 
P A gestationalDiabetes 115 -41.61016 87.22032 9.56 0.0020 
Q A HIVstate 121 -49.08378 102.1676 0.05 0.8210 
R 
A educationLevel1 educationLevel2 
educationLevel3 117 -46.20089 100.4018 0.97 0.0806 
S A DMSymptoms 121 -48.09229 100.1846 2.03 0.1538 
T A lowFruitIntake 121 -49.04004 102.0801 0.14 0.7096 
U A lowVegIntake 121 -49.04004 102.0801 0.14 0.7096 
W A sendOccu 115 -44.87114 93.74228 3.04 0.0815 
Model P: gestationalDiabetes + ___ 
B1 P combHPTN 115 -40.87997 87.75993 1.46 0.2269 
C1 P ageCat0 ageCat2 ageCat3 115 -39.4182 88.83641 4.38 0.2229 
D1 P sendOccu 114 -40.3179 86.63579 2.35 0.1253 
E1 
P incomeCats2 incomeCats3 
incomeCats4 incomeCats5 98 -35.75856 83.51712 0.41 0.9818 
F1 P combineIncome 98 -35.96004 77.92008 0.00 0.9454 
G1 P PatnerStatus1 PatnerStatus2 115 -39.86705 87.73409 3.49 0.1750 
H1 P alc12mnth30day 115 -41.23039 88.46077 0.76 0.3835 
J1 P PAstatus 114 -41.40462 88.80923 0.18 0.6743 
K1 P BMIcat0 BMIcat2 BMIcat3 94 -33.29045 76.58089 1.75 0.6250 
L1 P BMI 94 -33.96479 73.92958 0.41 0.5243 
M1 P Waistcircumference 87 -32.41208 70.82417 1.79 0.1810 
N1 P highWC 87 -33.06512 72.13023 0.48 0.4867 
O1 P DiabetesFamilyHistory 115 -40.73871 87.47742 1.74 0.1868 
Q1 P HIVstate 115 -40.93456 87.86913 1.35 0.2451 
R1 
P educationLevel1 educationLevel2 
educationLevel3 117 -46.20089 100.4018 -9.18 1.0000 
S1 P DMSymptoms 115 -41.17296 88.34592 0.87 0.3497 
T1 P lowFruitIntake 114 -41.49295 86.9859 -0.23 . 
U1 P lowVegeIntake 114 -41.49295 86.9859 -0.23 . 




Figure D-4: Goodness of fit output for final DM model among females (model P) 
 
The model with just gestational diabetes was not a good fit (with Pearson goodness of fit < 
0.000). Age categories were added to the model because among females, it seemed to be 
slightly associated with DM and improved the model fit better that other risk factors. 
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